Podcasts about Lancet

Welcome to the latest Midlife Minute. This episode unpacks ongoing research on Lp(a), explores how women's lipids change during the perimenopause-to-menopause transition, and clarifies what we can do about it. Stay tuned for more! IN THIS EPISODE, YOU WILL LEARN: How total cholesterol, LDL, and ApoB tend to rise most steeply around the final menstrual period, rather than increasing gradually with chronological aging Why women should have their Lp(a) checked both before and after menopause How oral and transdermal estradiol can affect LDL, HDL, triglycerides, and Lp(a) differently Why I recommend including ApoB when checking your lipids during the perimenopause window How your lifestyle can reduce your cardiovascular risk, even when your Lp(a) is elevated Why omega-3 fatty acids and commonly used lipid medications do not lower Lp(a) Why supplements are not replacements for statins in genuinely high-risk patients  I review the various PCSK9 inhibitors currently available, how they are administered, and their effects  How a CAC, a CT angiogram, and an AI-assisted CT angiogram can help women and their providers determine how aggressive their approach should be when Lp(a) is elevated Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line References: 1. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association.Circulation. 2020. El Khoudary SR, Aggarwal B, Beckie TM, et al.Guideline 2. Menopause: A Cardiometabolic Transition. The Lancet. Diabetes & Endocrinology. 2022. Nappi RE, Chedraui P, Lambrinoudaki I, Simoncini T.Review 3. Dyslipidemia Across the Menopause Transition: Mechanisms, Trajectories, and Opportunities for Cardiovascular Prevention. Maturitas. 2026. Castaneda R, Tatit CP, Hurtado Andrade MD, Faubion SS, Shufelt CL.RecentReview 4. Lipoprotein(a) and Women's Cardiovascular Health: A Review. JACC. Advances. 2026. Michos ED, Saucier S, Mehran R, Koschinsky ML. 5. Lipid Metabolism in Women: A Review. Atherosclerosis. 2025. van Oortmerssen JAE, Mulder JWCM, Kavousi M, Roeters van Lennep JE.Review 6. Are Changes in Cardiovascular Disease Risk Factors in Midlife Women Due to Chronological Aging or to the Menopausal Transition?. Journal of the American College of Cardiology. 2009. Matthews KA, Crawford SL, Chae CU, et al.Observational 7. Trajectories of Lipids Around the Menopause Transition in Chinese Women: Results of the Kailuan Cohort Study. Fertility and Sterility. 2023. Dai Q, Wu S, Cao Z, et al. 8. Lipid Management in Patients With Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism. 2020. Newman CB, Blaha MJ, Boord JB, et al.Guideline 9. The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2022. Nie G, Yang X, Wang Y, et al.SR 10. Perspectives on Dyslipidemia and Coronary Heart Disease in Women. Journal of the American College of Cardiology. 2005. Bittner V.Review 11. Dyslipidemia in Midlife Women: Approach and Considerations During the Menopausal Transition. Maturitas. 2022. Torosyan N, Visrodia P, Torbati T, Minissian MB, Shufelt CL.Review 12. Effects of gender, age and menopausal status on serum apolipoprotein concentrations.13.Lipoprotein(a).The Journal of the American Medical Association. 2025. Mora S, Kronenberg     14. Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications. Diabetes, Obesity & Metabolism. 2025. Razavi AC, Bhatia HS, Blumenthal RS, Shapiro MD, Mehta A.RecentReview 15. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. Journal of the American College of Cardiology. 2021. Cicero AFG, Fogacci F, Zambon A.Review 16. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs. 2023. Blais JE, Huang X, Zhao JV.SR 17. Non-Genetic Influences on Lipoprotein(a) Concentrations. Atherosclerosis. 2022. Enkhmaa B, Berglund L.Review 18. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the American College of Cardiology. 2018. Tsimikas S, Fazio S, Ferdinand KC, et al.Review 19. Consumption of a defined, plant‐based diet reduces lipoprotein(a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks. Clinical Cardiology. 2018. Najjar RS, Moore CE, Montgomery BD. 20. Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies. Clinical Therapeutics. 2019. Santos HO, Kones R, Rumana U, et al.Review 21. Effect of Lipid-Lowering Therapies on Lipoprotein(a) Levels: A Comprehensive Meta-Analysis of Randomized Controlled Trials. Atherosclerosis. 2025. Xie S, Galimberti F, Olmastroni E, et al.Recent 22. Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis. 2023. Ying Q, Croyal M, Chan DC, et al.RCT 23.Lipoprotein(a) and Cardiovascular Disease. Lancet. 2024. Nordestgaard BG, Langsted A.Review 24. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022. Reyes-Soffer G, Ginsberg HN, Berglund L, et al.Guideline 25.Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3.Journal of the American College of Cardiology. 2023. Malick WA, Goonewardena SN, Koenig W, Rosenson RS.Review 26.2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American Collegeof Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026. Writing Committee Members, Blumenthal RS, Morris PB, et al.Guideline 27. Noninvasive Coronary Atherosclerotic Plaque Imaging. JACC. Cardiovascular Imaging. 2023. Kwiecinski J, Tzolos E, Williams MC, et al.Review 28. Computed Tomography Angiography Versus Agatston Score for Diagnosis of Coronary Artery Disease in Patients With Stable Chest Pain: Individual Patient Data Meta-Analysis of the International COME-CCT Consortium. European Radiology. 2022. Wieske V, Walther M, Dubourg B, et al.SR 29. Association of Coronary Artery Calcium Score With Qualitatively and Quantitatively Assessed Adverse Plaque on Coronary CT Angiography in the SCOT-HEART Trial. European Heart Journal. Cardiovascular Imaging. 2022. Osborne-Grinter M, Kwiecinski J, Doris M, et al.Clinical Trial 30. AI-Guided Quantitative Plaque Staging Predicts Long-Term Cardiovascular Outcomes in Patients at Risk for Atherosclerotic CVD. JACC. Cardiovascular Imaging. 2024. Nurmohamed NS, Bom MJ, Jukema RA, et al.Observational 31. The Lancet Commission on Rethinking Coronary Artery Disease: Moving From Ischemia to Atheroma. Lancet. 2025. Zaman S, Wasfy JH, Kapil V, et al.Review 32. Efficacy and safety of novel lipoprotein(a)‐targeted therapies: A systematic review and meta‐analysis of randomized controlled trials. Diabetes, Obesity & Metabolism. 2026. Santana AUL, Yusufzai MO, Freitas APS, et al. Recent Opinion

Acute Appendicitis explained, including classic and atypical appendicitis symptoms, the pathophysiology of appendicitis, as well as causes, diagnosis (including scores like the Alvarado score) and treatment.PDFs available here: https://rhesusmedicine.com/products/general-surgeryConsider subscribing on YouTube (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Appendicitis?0:32 Appendicitis Pathophysiology2:00 Causes of Appendicitis2:59 Appendicitis Symptoms & Signs 5:29 Appendicitis Diagnosis8:44 Appendicitis Treatment / Appendectomy LINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/Please remember this podcast and all content from Rhesus Medicine is meant for educational purposes only and should not be used as a guide to diagnose or to treat. Please consult a healthcare professional for medical advice. ReferencesBMJ Best Practice (2026) Acute appendicitis. Available at: https://bestpractice.bmj.com/topics/en-gb/3000094Di Saverio, S., Podda, M., De Simone, B., et al. (2020) 'Diagnosis and treatment of acute appendicitis: 2020 update of the WSES Jerusalem guidelines', World Journal of Emergency Surgery, 15(1), p.27. Available at: https://wjes.biomedcentral.com/articles/10.1186/s13017-020-00306-3Moris, D., Paulson, E.K. and Pappas, T.N. (2021) 'Diagnosis and management of acute appendicitis in adults: a review', JAMA, 326(22), pp.2299-2311. Available at: http://www.ncbi.nlm.nih.gov/pubmed/34905026MSD Manual (2024) Appendicitis. Available at: https://www.msdmanuals.com/professional/gastrointestinal-disorders/acute-abdomen-and-surgical-gastroenterology/appendicitisStatPearls Publishing (2024) Appendicitis. Available at: https://www.ncbi.nlm.nih.gov/books/NBK493193/Bhangu, A., Søreide, K., Di Saverio, S., Assarsson, J.H. and Drake, F.T. (2015) 'Acute appendicitis: modern understanding of pathogenesis, diagnosis, and management', The Lancet, 386(10000), pp.1278-1287. Available at: https://pubmed.ncbi.nlm.nih.gov/26460662Flum, D.R., Davidson, G.H., Monsell, S.E., et al. (2020) 'A randomized trial comparing antibiotics with appendectomy for appendicitis', New England Journal of Medicine, 383(20), pp.1907-1919. Available at: https://pubmed.ncbi.nlm.nih.gov/33017106Addiss, D.G., Shaffer, N., Fowler, B.S. and Tauxe, R.V. (1990) 'The epidemiology of appendicitis and appendectomy in the United States', American Journal of Epidemiology, 132(5), pp.910-925. Available at: https://pubmed.ncbi.nlm.nih.gov/2239906

An update of the 2015 WHO estimates of foodborne disease shows that in 2021 alone, transmission of 42 different hazards in food caused 866 million illnesses and 1.52 million deaths. So what can be done about this huge burden of illness? How is data like this collated? And what don't we know? Yuki Minato and Rob Lake, two authors of the papers, join Gavin Cleaver, senior editor at The Lancet Global Health, to discuss. Click here to read the full series: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00156-7/fulltext https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00143-9/fulltext https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00144-0/fulltext https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00159-2/fulltext https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00148-8/fulltext   The Lancet global Health in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: Editor-in-Chief Zoë Mullan, acting deputy editor Pingyue Jin, senior editors Shangrong Han, and Gavin Cleaver. Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more.  Find the best science for better lives at thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

(Rec: 31/5/23) Pigs in The Lancet, DNA, coining trouble, sexy eye patches, pig speed, pig sound, being eaten by pets, and a mixed grill in a bag. Join the Iron Filings Society: https://www.patreon.com/topflighttimemachine and on Apple Podcast Subscriptions. Get a 7-day full access free trial and pay for 10 months up front for the price of 12 if you like a bargain. Hosted on Acast. See acast.com/privacy for more information.

Is gluten really wrecking your thyroid and brain? Part 2 breaks down the devastating effects of amylase trypsin inhibitors, where celiac disease ends and gluten/wheat sensitivity begubs, and the real evidence on gluten's cross-reactivity with Hashimoto's — plus how to test for it properly.In Part 2 of this deep-dive, Dr. Steven Noseworthy picks up where Part 1 left off with the other non-gluten protein doing serious damage: amylase trypsin inhibitors (ATIs), which trigger their own transient leaky gut and — per 2020 research — remodel your gut microbiome the same way a course of antibiotics would. From there he draws the real line between celiac disease and non-celiac wheat sensitivity, walks through a November 2025 Lancet review on the gut-brain side of "gluten sensitivity," and takes an honest look at gluten's effect on blood flow to the brain and whether it actually cross-reacts with your thyroid in Hashimoto's. The episode closes with how to actually test for a gluten problem instead of guessing your way through an elimination diet.

Welcome to the latest Midlife Minute. Today, I'm answering listeners' questions about cardiovascular risk, focusing on Lp(a), LDL, statins, and the changes women experience after menopause. Stay tuned for more! IN THIS EPISODE, YOU WILL LEARN: Why women should have their Lp(a) checked both before and after menopause How Lp(a) works as a risk enhancer, and how cardiovascular risk becomes more significant when elevated Lp(a) occurs alongside high LDL Why family history is particularly helpful for women with a 10-year calculated cardiovascular risk that looks reassuringly low I review the current guidelines for primary prevention Why, even though research has shown reductions in major cardiac events with GLP-1s, GLP-1s do not replace statins for lowering LDL  What a CAC score can reveal about coronary artery calcification, and what it cannot detect How AI-assisted CT angiography (such as Clearly) can map, quantify, and characterize plaque throughout the coronary branches Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line References: 1.  ​Lipoprotein(a) and Women's Cardiovascular Health: A Review. JACC. Advances. 2026. Michos ED, Saucier S, Mehran R, Koschinsky ML.Recent 2.  ​Sex Differences of Lipoprotein(a) Levels and Associated Risk of Morbidity and Mortality by Age: The Copenhagen General Population Study. Atherosclerosis. 2022. Simony SB, Mortensen MB, Langsted A, et al. 3. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2022. Stone NJ, Smith SC, Orringer CE, et al.Review 4. Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a). JAMA Cardiology. 2026. Nordestgaard AT, Chasman DI, Moorthy V, et al.RecentObservational 5.  ​Lipoprotein(a).The Journal of the American Medical Association. 2025. Mora S, Kronenberg  6. Clinical Practice Guideline on Lipid Management for Cardiovascular Disease Risk Reduction. Department of Veterans Affairs (2026). 2026. Paul Heidenreich, Lance Spacek, Neil Gregor, et al. Guideline 7. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. Journal of the American College of Cardiology. 2020. Mehta A, Virani SS, Ayers CR, et al.Observational 8. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2010. Greenland P, Alpert JS, Beller GA, et al.Guideline 9. Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women. The Journal of the American Medical Association. 2016. Kavousi M, Desai CS, Ayers C, et al.SR 10. ​Coronary Artery Calcium Scores and Risk for Cardiovascular Events in Women Classified as “Low Risk” Based on Framingham Risk Score: The Multi-Ethnic Study of Atherosclerosis (MESA). Archives of Internal Medicine. 2007. Lakoski SG, Greenland P, Wong ND, et al.Observational 11. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019. Arnett DK, Blumenthal RS, Albert MA, et al.Guideline 12. HOPE for Rational Statin Allocation for Primary Prevention: A Coronary Artery Calcium Picture Is Worth 1000 Words. Mayo Clinic Proceedings. 2020. Orringer CE, Maki KC.Review 13. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020. Cho L, Davis M, Elgendy I, et al.Review 14. Health Maintenance in Postmenopausal Women. American Family Physician. 2025. Plesa M, Wong A, Katsaggelos E.Guideline 15.  ​Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care. 2024. Lingvay I, Deanfield J, Kahn SE, et al.RCT 16.  ​Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine. 2023. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.RCT 17. Long-Term Weight Loss Effects of Semaglutide in Obesity Without Diabetes in the SELECT Trial. Nature Medicine. 2024. Ryan DH, Lingvay I, Deanfield J, et al.RCT 18. Interventions for the Prevention and Management of Cardiometabolic Multiple Long-Term Conditions. Lancet. 2026. Valabhji J, Hope D, Sayed NE, et al.RecentReview 19. Glucagon‐Like Peptide‐1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta‐Analysis of Randomized‐Controlled Trials. Clinical Cardiology. 2024. Hosseinpour A, Sood A, Kamalpour J, et al.SR 20. ​FDA Orange Book. FDA Orange Book. 2026. 21. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026. American Diabetes Association Professional Practice Committee for Diabetes*.RecentGuideline 22. Premature Coronary Artery Disease in Women: Sex-Specific Risk Factors, Pathogenetic Mechanisms and Clinical Implications. Annals of Medicine. 2026. Li F, Hong D, Yang M, et al.RecentReview 23. Cardiovascular Disease Risk Factors in Women: The Impact of Race and Ethnicity: A Scientific Statement From the American Heart Association. Circulation. 2023. Mehta LS, Velarde GP, Lewey J, et al.Guideline 24. Preventing CVD in Women: Common Questions and Answers. American Family Physician. 2023. Westfall E, Viere AB, Genewick JE.Review 25. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020. El Khoudary SR, Aggarwal B, Beckie TM, et al.Guideline

Brain Health Reset: 9 Weeks to Better Energy, Focus & Sleephttps://rawfoodmealplanner.kit.com/549de1dbb2 Join January 2027 RawFoodMealPlanner's 21-Day Challengehttps://rawfoodhealthempowermentsummit.com/the-rawfoodmealplanner-s-21-day-new-year-meal-prep-challenge Boost Your Wellness Journey:The Brain Reboot Plan: 5 Simple Daily Shifts for More Focus, Energy & Peacehttps://rawfoodmealplanner.com/brain-reboot-plan/Revitalize Your Brain: A Lifestyle Approach for Women Over 50https://rawfoodmealplanner.clickfunnels.com/webinar-replay-brain-health-breakthrough-coaching-programRESET: 3 Metabolic Mistakes Women 30+ Make And How to Fix Themhttps://rawfoodmealplanner.com/reset-3-metabolic-mistakes-women-30-make-and-how-to-fix-them/The Lancet published a study here https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(24)00191-0/fulltext emphasizing that young adults (ages 18–39) are a neglected but crucial window for dementia prevention. Most dementia research focuses on mid-to-late life, yet many modifiable risk factors that affect long-term brain health emerge or peak in young adulthood.Key Modifiable Risk FactorsEducation: Low levels reduce cognitive reserve and increase the risk of dementia.Hearing loss: One billion young adults globally are at risk due to unsafe listening practices.Traumatic brain injury (TBI): High rates from sports, motor accidents, and intimate partner violence.Hypertension: One in 12 young adults is affected; rates higher among Black Americans and in LMICs.Alcohol use: Peaks in early 20s, linked to long-term brain changes.Obesity & physical inactivity: Both rising rapidly; linked to inflammation and cardiovascular risk.Smoking/vaping: 90% of daily smokers start before 26.Depression & social isolation: Peak in early 20s, linked to later ADRD (Alzheimer's disease and related dementias) risk.Diabetes: 4% prevalence in young adults; prediabetes affects 1 in 4.Environmental factors: Air pollution, vision loss, high LDL cholesterol, and even emerging risks like sleep disruption, stress, spirituality, and microplastics.Join the Conversation:Subscribe and share this episode with anyone on their own path of health and transformation. // HOST Samantha Salmon, NBC-HWC Nationally Board Certified Health & Wellness Coach Brain Health Licensed Trainer | Integrative Nutrition Coach | Intuitive Nutrition Coach for Brain & Metabolic HealthThe information provided in this broadcast is for educational purposes only and is not intended as medical advice. These statements have not been evaluated by the Food and Drug Administration or the equivalent in your country. Any products/services mentioned are not intended to diagnose, treat, cure, or prevent disease. RawFoodMealPlanner.com © 2026

*JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]*Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2 *HEALTH AUTONOMY [COURSE]*Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy*JOIN THE COMMUNITY*Join my Community [It's Free!]: https://bit.ly/PhysionicCommunity2*EMAIL LIST*1-2 Weekly Email of Value [It's Free!]: http://bit.ly/2AXIzK6*HIRE ME FOR CONSULTING:* Consulting: https://bit.ly/3dmUl2H Original Podcast: https://youtu.be/q57CNySsYxs?si=PIwVEVGj_-cYkDCU0:00 - Introduction1:54 - Genetics that cause High Cholesterol5:29 - The American Heart Association is lying to you8:05 - Extremely High Cholesterol doesn't Kill17:48 - High Cholesterol at 60? Protection from Death25:20 - Other ways of testing this?27:12 - Main PointsReferences[1] Mundal L, Sarancic M, Ose L, et al. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992–2010. *J Am Heart Assoc*. 2014;3(6):e001236. doi:10.1161/JAHA.114.001236[2] Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. *Proc Natl Acad Sci U S A*. 1974;71(3):788-792. doi:10.1073/pnas.71.3.788[3] Shishikura D, Harada-Shiba M, Michikura M, et al. Comparison of clinical characterization and therapeutic strategies between homozygous familial hypercholesterolemia and heterozygous familial hypercholesterolemia. *J Atheroscler Thromb*. 2026;33. Advance publication online March 27, 2026. doi:10.5551/jat.65959[4] Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. *Lancet*. 2004;363(9406):369-370. doi:10.1016/S0140-6736(04)15467-6[5] EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Lancet*. 2021;398(10312):1713-1725. doi:10.1016/S0140-6736(21)01122-3[6] Clarke R, Emberson JR, Parish S, et al. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. *Arch Intern Med.* 2007;167(13):1373-1378.[7] Ding M, Wennberg A, Ek S, et al. The association of apolipoproteins with later-life all-cause and cardiovascular mortality: a population-based study stratified by age. *Sci Rep.* 2021;11(1):24440. doi:10.1038/s41598-021-03959-5.[8] Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. *Lancet*. 2020;396(10263):1644-1652. doi:10.1016/S0140-6736(20)32233-9Please use the following link to submit your critique: https://bit.ly/PhysionicCritiqueDisclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

In this episode of the Race and Rights Podcast, guest host Dr. Esaa Mohammad Sabti Samarah sits down with Dr. Mustafa Rfat, a faculty member at the University of Nebraska at Omaha, a scholar of forced migration and disability justice, and the Refugee Congress Delegate representing the state of Missouri, for a conversation examining the intersection of refugee rights, disability, and structural inequality. Drawing from both rigorous scholarship and lived experience as a refugee with a disability, Dr. Rfat explores how immigration systems, social policies, and institutional practices shape the lives of refugees with disabilities long before and long after resettlement.Together, they examine the historical exclusion of people with disabilities from U.S. immigration and citizenship policy, the barriers refugees encounter when navigating health care, education, employment, and naturalization, and why disability must be understood through a social rather than medical lens alone. The discussion also explores the human consequences of recent refugee and deportation policies, highlighting how inaccessible systems and language exclusion can undermine both disability rights and fundamental human rights.Throughout the conversation, Dr. Rfat reflects on his own journey from Iraq to the United States, illustrating how personal experience has informed a research agenda dedicated to advancing refugee health equity, participatory research, and disability justice. The episode challenges listeners to reconsider dominant narratives about refugees by centering resilience, dignity, and belonging while emphasizing the responsibility of researchers, practitioners, and policymakers to dismantle structural barriers rather than expecting individuals to overcome them alone.This episode is essential listening for scholars, practitioners, policymakers, students, and advocates committed to refugee rights, disability justice, health equity, and human rights.Links to Published WorksRfat, M. (2026). Path to Citizenship: Addressing the Needs of Refugees with Disabilities in the Naturalization Process. Journal of Human Rights and Social Work. Rfat, M., Zeng, Y., Yang, Y., Adhikari, K., & Zhu, Y. (2023). A Scoping Review of Needs and Barriers to Achieving a Livable Life among Refugees with Disabilities: Implications for Future Research, Practice, and Policy. Journal of Evidence-Based Social Work. Rfat, M., Zeng, Y., & Trani, J.-F. (2023). Exploring the Intersectionality of Disability and Refugee Statuses: Reflecting on My Refugee Journey. British Journal of Social Work. Rfat, M., Cureton, A., Mirza, M., & Trani, J.-F. (2025). The Devastating Effect of Abrupt U.S. Refugee Policy Shifts. The Lancet. Rfat, M., Engelman, A., & Seaborn, S. (2026). US Forced Deportation, Language Exclusion, and Disability Justice. The Lancet. Rfat, M., Yang, Y., & Cohen, F. (2025). Benefits and Challenges of Using Participatory Research Among Refugees With Disabilities: A Scoping Review. Health Education & Behavior. #RefugeeRights #DisabilityJustice #HealthEquity #ForcedMigration #HumanRights #SocialWork #RefugeeHealth #Accessibility #MigrationJustice Support the showSupport the Center for Security, Race and Rights by following us and making a donation:Donate: https://give.rutgersfoundation.org/csrr-support/20046.html Subscribe to our Youtube Channel: https://www.youtube.com/playlist?list=PLEbUfYcWGZapBNYvCObiCpp3qtxgH_jFy Follow us on Twitter: https://twitter.com/rucsrr Follow us on Instagram: https://instagram.com/rutgerscsrr Follow us on Threads: https://threads.com/rutgerscsrr Follow us on Facebook: https://facebook.com/rucsrr Follow us on TikTok: https://tiktok.com/rucsrr 

“We're hardwired for love. We are taught to do violence, and to hate.” — Dana Mashoian Walrath A couple of months ago in Warsaw, the Polish writer and Jewish activist Konstanty Gebert argued that Gaza wasn't a genocide. Today's guest disagrees. In The Book of Genocides, graphic artist and anthropologist Dana Mashoian Walrath draws ten genocides including what she sees as the crimes against humanity committed by the Israeli army in Gaza. So what, exactly, is a “genocide”? Walrath's definition borrows from the Polish lawyer Raphael Lemkin, who coined the term during the Second World War. Lemkin meant the word to mean the destruction of peoples that had been deemed sub-human. Thus Walrath includes crimes against the First Peoples of the Americas and Black Americans alongside 20th-century mass killings in Cambodia, Rwanda, Bosnia and Armenia, where her ancestors were persecuted. Some will quibble over this list. Although quibbling over the top (or bottom) ten genocides isn't exactly good taste. Besides, The Book of Genocides is a poignant work of graphic art in the tradition of Art Spiegelman's Maus. And its author, for all her anthropological insights into why people commit crimes against humanity, isn't shy with her genocide jokes. Springtime for Hitler, anyone? Five Takeaways •       Always a Land Grab. Ten genocides across five centuries — the First Peoples of the Americas, Black Americans, Aboriginal Australians, Armenia, the Holocaust, Cambodia, Rwanda, Bosnia, the Rohingya, and Gaza — chosen not to rank horrors but to expose “the repetitive patterns and the processes that underlie genocide.” Walrath's definition is Raphael Lemkin's original, processual one, before politics narrowed the convention: the purpose is always a land grab, the apparatus always dehumanization, and precise academic definitions are often deployed “to keep some stories and histories out.” The book began as an interactive art installation with nine genocides and a tenth chapter on “the borders of genocide” — Afghanistan, Vietnam, Congo, Ukraine, Palestine — until the violence in Gaza persuaded her to make the case outright, while insisting the aim is not to demonize her Jewish friends, Judaism, or Israel, but to show the system. Her hope: that a globally framed comic might open dialogue between Jews and Palestinians “trapped in enmity right now.”•       Lemkin's Last Train. The man who coined the word is the book's tragic through-line. As a Polish law student, Lemkin followed the Berlin trial of a young Armenian who had shot one of the architects of the Armenian genocide — and found it ludicrous that the assassin faced justice for one murder while his victim had answered for none of his millions. His family farm had been seized in the First World War; his brother Samuel died in the forest. He escaped Warsaw on a train that was bombed, ran by night to reach his family, and failed to persuade them to leave (“they do this to us all the time”). Via Sweden, Russia, Japan, and Duke, he spent the war in Washington trying to make Americans see. His convention passed — then waited years for the US, UK, and China to ratify — and he died in 1959 penniless and friendless, UN officials fleeing him in the corridors. Walrath's speculation: his great regret, looking down, may be refusing to support We Charge Genocide, the 1951 petition by Black Americans — “we can't talk about something America has done” in the Cold War. Had America owned and repaired that crime then, “we'd be in a very different world.”•       Can You Have Half a Genocide? Andrew's pushback — if politicians can be “verging on genocidal,” does every Karen yelling at her kids get accused of it? — drew the hour's most honest concession: “that's the absolute spot-on critique of the approach I've taken.” Her defense is preventive: half a genocide is “too quantitative”; better to name things “on their way to massacre” and stop them, or repair them, than to litigate the label afterward. Genocide, she argues, predates modernity and Arendt's industrial reading — it arrives with the first hierarchical, extracting, wealth-inheriting “so-called civilizations,” Sparta and Thucydides included. Slavery qualifies because the operational word is systemic: the transatlantic trade ran on thinking of humans as lesser. But she draws one line firmly: asked about factory farms as future genocides, “I would hate to see genocide get used over there. It is something that humans do to one another” — and, she insists, don't have to: the literature on aversion to killing shows soldiers must be socialized into it. We're hardwired for love and taught to hate.•       Stanton's Stages in MAGA America. Is there something genocidal in MAGA's language about undocumented immigrants? “Absolutely.” Walrath applies the ten stages of genocide — the classroom heuristic Gregory Stanton first presented to the State Department in 1996 — and finds the United States “doing a heck of a lot of them”: polarization; dehumanization (people called vermin, “not worthy of life”); discrimination in the restriction of voting rights. “We're on very, very shaky ground.” Homelessness, in the same frame, is the product of structures that disenfranchise some and privilege others — “we've got enough to go around; we just revere wealth.” Her model for how ordinary people let it happen is Ursula Hegi's Stones from the River: the fearful, the wounded, the disenfranchised, vulnerable to takeover — with parallels in MAGA voters spurned by the neoliberal machine and unable to see who is pulling the levers. Hence her claim for the book: it is resistance, but resistance that builds a coalition across horrors rather than policing which horror counts.•       Springtime for Hitler. She didn't read Maus until 2009 — “that's when I found my medium and just went wild” — and pays it explicit homage in the book. Comics, she argues, let readers “come into” a history and think for themselves, and laughter is respite: an angry messenger gets no listeners. Her earlier Aliceheimer's let people laugh about her mother's dementia (not at it, she corrected sharply); telling audiences she's working on her genocide jokes makes them relax enough to hear the rest. Andrew's challenge — “do you really want to make it safe?” — produced the useful distinction: safe to enter, not whitewashed; hand-lettered so readers can bring the content in, every truth intact. The closing exchange landed on The Producers and Springtime for Hitler as a brilliant portrayal of the legacies of catastrophe. Her last word: knowledge must cross boundaries, “and the boundaries are all human made, so let's unmake them.” Andrew's: most will disagree with her list — and it may be a classic. About the Guest Dana Mashoian Walrath is a writer, artist, and anthropologist. Her award-winning works include Aliceheimer's, a graphic memoir about her mother's dementia, and Like Water on Stone, a verse novel about the Armenian genocide. She holds a doctorate in anthropology from the University of Pennsylvania; her comics, art, essays, and poetry have appeared in The Nation, The Lancet, Slate, and on NPR. The Book of Genocide...

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.75 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-500 Overview: To celebrate our 500th episode, each member of our team revisits a popular topic from the podcast's earlier installments—GLP-1s, cervical and breast cancer screening, diet and exercise, contraception, hypertension, and lipid management—to trace how the evidence and guidelines have changed since it was first covered. Whether you're catching up or reinforcing what you know, this milestone episode helps you bring the latest evidence into everyday patient care. Guest: Robert Baldor, MD, Alan Ehrlich, MD, Susan Feeney, DNP, FNP-BC; FAANP, Jillian Joseph, PA, Mariyan L. Montaque, DNP, FNP-BC, Jill Terrien PhD, ANP-BC, FAAN   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  Episode resource links:  Zhou H et al.  Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10‐Year Atherosclerotic Cardiovascular Risk Prediction. Journal of the American Heart Association Volume 14, Number 4 Goff DC et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–S73. Circulation. 2018 Jul 24;138(4):345-355.  eClinicalMedicine 2025: 103741. Curry, J. (2018). Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA.320(7):674-686. doi:10.1001/jama.2018.10897 https://www.ncbi.nlm.nih.gov/pubmed/30140884  Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;e70041. doi:10.3322/caac.70041   Screening for Cervical Cancer (2026). Obstetrics & Gynecology, 148(1), e63-e67. https://doi.org/10.1097/AOG.0000000000006257  Jad Zeitouni, Nosayaba Osazuwa-Peters, Yusuf Dundar, Gregory Zimet, Mark A. Varvares. (2025). Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity, The Lancet Regional Health - Americas, (51), https://doi.org/10.1016/j.lana.2025.101243 Diabetes, Obesity and Metabolism 28, no. 6 (2026): 5043–5057, https://doi.org/10.1111/dom.70698.  Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026 Jul;139(7):913-921. doi: 10.1016/j.amjmed.2026.03.010 US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918–1930.  Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA. 2024;331(22):1931–1946. Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541.  Qaseem A, Harrod CS, Balk EM, et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (Version 2). Ann Intern Med. 2026.:  American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, 2022.  Hu X, Chehal PK, Kaplan C, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer. JAMA Netw Open. 2022;5(8):e2225485.  Torres JM, Sodipo MO, Hopkins MF, Chandler PD, Warner ET. Racial differences in breast cancer survival between Black and White women according to tumor subtype: a systematic review and meta-analysis. J Clin Oncol. 2024;42(35):4225–4234.  Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. Hypertension. 2026;83:00–00. DOI: 10.1161/HYPERTENSIONAHA.125.25787 Allen RH, Bartz D. Opill: The Over-the-Counter Contraceptive Pill. Obstet Gynecol. 2024;143(2):184-188. doi:10.1097/AOG.0000000000005455  Cahill EP, Kaur S. Advances in contraception research and development. Curr Opin Obstet Gynecol. 2020;32(6):393-398. doi:10.1097/GCO.0000000000000666  Charles DN, Nagarsheth M, Oshman L. Pain Management for IUD Insertion in Primary Care. Am Fam Physician. 2025;111(4):299-301.  Chen, C., Strasser, J., Banawa, R., Luo, Q., Bodas, M., Castruccio-Prince, C., Das, K., & Pittman, P. (2022). Who is providing contraception care in the United States? An observational study of the contraception workforce. American journal of obstetrics and gynecology, 226(2), 232.e1–232.e11. https://doi.org/10.1016/j.ajog.2021.08.015  Diedrich,J., Klein, D. Peipert, J.(2017). Long-acting reversible contraception in adolescents: a systematic review and meta-analysis, Am J Ob Gyn, April 2017. http://dx.doi.org/10.1016/j.ajog.2016.12.024  Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial. Lancet. 2023;402(10405):851-858. doi:10.1016/S0140-6736(23)01240-0  Mørch LS, Meaidi A, Corn G, Hargreave M, Wessel Skovlund C. Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024;332(18):1578–1580. doi:10.1001/jama.2024.18575  Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024;73(4):1-126. Published 2024 Aug 8. doi:10.15585/mmwr.rr7304a1  Paradise SL, Landis CA, Klein DA. Evidence Based Contraception: Common Questions and Answers. American Family Physician. 2022. https://www.aafp.org/afp/2022/0900/contraception The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

A íntegra do programa em português que foi ao ar ao vivo em rede nacional pela rádio SBS 2 da Austrália nesta quarta-feira. As notícias do dia. Também: conversamos com a psicóloga brasileira Camila Albuquerque, da Universidade de Queensland, especialista em depressão pós-parto. A universidade realizou o maior estudo de saúde perinatal do mundo, recentemente publicado na revista científica The Lancet. De Portugal, nosso correspondente Francisco Sena Santos fala sobre as denúncias de violência contra vulneráveis em Lisboa por parte da policia, contra pessoas com problemas de vício em drogas, imigrantes e sem-abrigos. Falaremos também sobre a crise na Volkswagen. A maior fabricante de carros da Europa passará por mudanças radicais. Contamos ainda sobre mudança na emissão de passaportes brasileiros.—-Siga a SBS em Português no Facebook, X, Instagram e You Tube. Siga a 'SBS Portuguese' no Spotify, Apple Podcasts, iHeart Podcasts, PocketCasts ou na sua plataforma de áudio favorita.

Weight maintenance is a challenging topic for both clinicians and patients. In this special episode, Neil Skolnik is joined by Jamie Almondoz, MD, who discusses the toxic narratives that have historically been part of the weight loss conversation, and the latest strategies for maintaining a healthy weight after the initial loss. This special episode is sponsored with support from Lilly. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Jamie Almondoz, MD, Professor of Internal Medicine and the Medical Director of the Weight Wellness Program at the University of Texas Southwestern Medical Center and Vice-Chair of the American Board of Obesity Medicine (ABOM) References: Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. June 2026; 407:2305-2318 Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial. JAMA 2021;325;(14):1414-1425 Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med 32, 2679–2687 (2026) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022; 24(8): 1553-1564

¡Mándame un mensaje!OZEMPIC ESTÁ CAMBIANDO ALGO MÁS QUE TU HAMBREPersonas que empezaron a usar semaglutida para bajar de peso comenzaron a reportar algo rarísimo: no sólo tenían menos hambre… algunas también tenían menos ganas de tomar alcohol.Al principio eran anécdotas. Ahora ya tenemos ensayos clínicos randomizados estudiando exactamente eso.Y aquí es donde el tema se pone mucho más interesante que “Ozempic hace que tomes menos”.En este episodio hablamos de qué están encontrando los estudios sobre semaglutida y consumo de alcohol, pero sobre todo usamos ese hallazgo para meternos en algo mucho más fascinante: cómo construye tu cerebro las ganas de querer algo.Porque “me gusta” y “lo quiero” no son exactamente la misma cosa.Puedes disfrutar una recompensa y tener menos impulso de ir por otra. También puedes querer algo muchísimo aunque ya ni siquiera lo disfrutes como antes. Hablamos de liking vs. wanting, de por qué una botella, un olor, una hora del día o incluso un lugar pueden disparar craving, de lo que realmente hace —y no hace— la dopamina y de cómo tu estado metabólico puede cambiar cuánto valor le asigna tu cerebro a una recompensa.Y ahí está el verdadero chisme de los GLP-1:Quizá no solamente nos están enseñando cómo funciona el hambre.También pueden estar ayudándonos a entender cómo funciona el “quiero más”.Ojo: semaglutida no es actualmente un tratamiento establecido específicamente para el trastorno por consumo de alcohol. La evidencia es prometedora, pero todavía estamos entendiendo quién responde, qué mecanismos explican los efectos y qué tan relevantes serán clínicamente a largo plazo.Y por cierto, si estás utilizando un GLP-1 para pérdida de peso, el medicamento no reemplaza entrenar. Preservar fuerza y masa muscular sigue siendo una prioridad.Si quieres empezar a entrenar fuerza conmigo, te dejo aquí el recomendador de programas wOS, con opciones para casa y gym y opciones para distintos niveles:

Citicoline and Stroke Recovery: What the Major Clinical Trials Actually Found If you’re recovering from a stroke or brain injury, there’s a familiar, exhausting question that shows up once the rehab schedule is set: is there anything else a supplement, a nutrient, something that could genuinely support the brain while it rebuilds itself? Citicoline comes up in that search constantly, across nootropic forums, supplement stores, and even some hospital protocols. It also happens to have one of the largest clinical trial records of any brain-recovery compound available. So rather than trusting a product label, it’s worth going straight to what those trials actually found, including the parts that didn’t work. What Citicoline Is Citicoline (cytidine diphosphate-choline, or CDP-choline) is a compound your body already produces. It’s a building block for phosphatidylcholine, a major structural component of neuronal cell membranes. The theory behind supplementing it is straightforward: give the brain more raw material to repair damaged membranes and support neurotransmitter production after an injury. It’s sold over the counter as a supplement (often branded as “Cognizin”), and in some countries it’s used clinically, including intravenously, in hospital stroke and TBI protocols. What the Major Trials Actually Show This is a case where the size of the evidence base is unusually large, and the results are humbling rather than triumphant. The ICTUS trial, published in The Lancet in 2012 with 2,298 patients, tested citicoline for acute ischemic stroke and found no significant benefit over placebo for global recovery at 90 days; the trial was stopped early for futility (PMID 22691567). The COBRIT trial, published in JAMA the same year with 1,213 traumatic brain injury patients, tested a higher dose of 2,000 mg per day for 90 days and again found no meaningful difference in functional or cognitive outcomes at 90 or 180 days (PMID 23168823). A 2020 Cochrane review pooling ten randomized trials and more than 4,000 stroke patients concluded there was little to no difference between citicoline and placebo in mortality, disability, or neurological recovery, and rated the overall evidence quality as low, noting six of the ten trials were industry-sponsored (PMID 32860632). Here’s where the picture becomes more interesting. A separate trial gave stroke survivors citicoline continuously for twelve months, rather than just during the acute phase, and found real improvements in attention, executive function, and temporal orientation compared to usual care, along with a non-significant trend toward better long-term functional outcome (PMID 23406981). A broader 2020 systematic review across neurological conditions similarly found citicoline useful for slowing dementia progression and enhancing cognition in healthy adults, while describing its effect on TBI specifically as “unclear” (PMID 33053828). A separate meta-analysis of twelve trials found citicoline significantly improved functional outcomes overall, even while showing no significant difference on several other individual outcome measures a genuinely mixed result rather than a clean positive or negative (PMID 28458415). The pattern that emerges: as a short-term rescue treatment for acute stroke or acute TBI, the largest, best-designed trials say no, it doesn’t move the needle. As a longer-term support for post-stroke cognitive function, taken consistently over months, there’s a more modest but real signal. What This Means for Stroke Survivors – The Honest Limits Citicoline is not an acute miracle treatment, and the largest trials in the field say so plainly. If you were hoping for a supplement that meaningfully changes outcomes in the days or weeks after a stroke, the evidence doesn’t support that expectation. The more genuine finding of better attention and executive function with twelve months of continuous use comes from a single open-label trial that wasn’t blinded, so it deserves a more cautious read than the large, definitive negative trials. There’s also a dosing gap worth knowing about before anyone assumes a supplement bottle reflects the research: clinical trials used 500 to 2,000 mg per day, often for months, while most over-the-counter citicoline products are dosed at 250 to 500 mg per day, meaningfully lower than the doses that produced the modest cognitive signal. Practical Takeaways – Questions to Bring to Your Treating Team Ask your neurologist or doctor whether citicoline makes sense for your specific recovery stage. Acute stroke support and long-term cognitive support are different questions with different evidence behind them. If you’re considering a supplement, check the label dose against what was actually studied. A product dosed well below 500 mg per day is not comparable to the trials that showed a cognitive benefit. Search “ICTUS citicoline,” “COBRIT trial,” or “citicoline cognitive stroke” on PubMed yourself, and form your own view. The honest picture here is nuanced enough that it’s worth reading past the marketing copy. The value of citicoline, if it exists for you, isn’t as a substitute for rehab, sleep, movement, and nutrition; it’s a small addition on top of everything else you’re already doing well, chosen because you understand the actual trial record rather than a supplement label. For the broader framework I used to separate genuine evidence from supplement hype throughout my own recovery, see my book: https://recoveryafterstroke.com/book. If breakdowns like this one are useful to you, the Recovery After Stroke Patreon (https://patreon.com/recoveryafterstroke) directly funds more of them. This blog is for informational purposes only and does not constitute medical advice. Please consult your doctor before making any changes to your health or recovery plan. The post Citicoline for Brain Recovery: What the Major Trials Actually Found appeared first on Recovery After Stroke.

Hosts: Ed Jones (Owner – Nutrition World) & Clint Powell A variety of topics all related to living a healthy life Presented by: Nutrition World www.nutritionw.com Broadcasting from the Nooga Dentistry Studio www.noogadentistry.com Production of: Whitfield Media Group www.vitalhealthradio.com Title: Post-COVID Gut Health and Rethinking Blood Pressure Targets   [0:04:24] – Nutrition World Health Fair & Upcoming Lectures Ed announces Nutrition World's Health Fair on October 24 (described as one of the biggest in the region). Emphasis on two “types of people”: learners vs. non‑learners; audience is framed as “learners.” Preview of free 30–40 minute lectures during the fair: Dave from Tonal Spine – energy systems and spinal health (non-traditional, beyond standard chiropractic). Laura Chastain – Optimize You – especially women's hormones; described as very skilled and experienced. Dr. Shalay (Chicago) – integrative healthcare, helping the body heal itself vs. “band-aid” approaches. Charles – Scenic City Neurotherapy – IV ketamine for: Chronic anxiety and depression PTSD Some applications in joint pain/arthritis (Ed notes his own experience for hip pain). Strong emphasis on root-cause medicine vs. symptom masking. [0:08:25] – Butter Wrappers & “Forever Chemicals” Ed raises a niche but practical topic: chemicals in butter wrappers. Refers to testing reported by Mammovation: Higher concern (more fluorine / “forever chemicals”): Kerrygold Pure Irish Butter Land O' Lakes salted butter Better / lower concern options: Kirkland (Costco) – lower levels Best butter wrappers listed: Whole Foods Market butter Horizon Kate's Salted Kirkland Organic Salted Butter Takeaway: Shop with knowledge; packaging/liners can be a hidden health variable. [0:12:50] – Nurse Practitioner Meredith Mason (Brio Functional Medicine) Introduction: Guest: Meredith Mason, NP, founder of Brio Functional Medicine (opened in 2018). Ed recalls having her on roughly seven years ago. COVID & long-COVID context: Meredith had two years of practice before COVID; she values that pre-COVID baseline. Notes a “triad” she sees repeatedly since COVID: Chronic fatigue Mast cell / high-histamine symptoms Digestive complaints / gut issues Clinic intake includes a 20-page questionnaire; many patients answer “When did you last feel well?” with: “2019” “Before I had COVID” “Before COVID vaccination” Meredith's personal health journey: At ~18–19, she had a mysterious illness with severe throat infection, ER visit, fatigue, and eventual chronic pain and fatigue. This pushed her toward integrative and root-cause medicine. COVID leading to apparent Epstein–Barr reactivation: After an infection in late 2021, she develops: Marked fatigue Mast-cell-type histamine issues Digestive symptoms Suspects Epstein–Barr virus (EBV) reactivation, not just mitochondrial dysfunction. Meredith's own approach: Used a Kasia Kines‑style nutritional protocol plus antivirals with a Florida physician. Her Early Antigen D normalized, with improved fatigue. EBV & herpesvirus family: Clarifies: Epstein–Barr is a herpesvirus, in the same family as: CMV (cytomegalovirus) HSV-1/HSV-2 Varicella (chickenpox) High-dose lysine known to slow replication of herpes viruses. [0:23:14] – H. pylori, Histamine Intolerance & Post-COVID Gut Changes Meredith's own mast-cell / histamine journey: Developed severe histamine symptoms post-COVID. Conventional H1 and H2 blockers (Claritin, Zyrtec, Pepcid/Famotidine) did not resolve issues. She also tried quercetin, luteolin, and evaluated genetics (DAO and HNMT) but didn't find a complete explanation. Turning to the gut: Ordered a GI-MAP functional stool test and found: Citrobacter freundii and Klebsiella pneumoniae – both high histamine‑producing bacteria. Hypothesis: COVID changes the gut microbiome (e.g., lowering beneficial Bifidobacteria), creating an environment for histamine­‑producing species to overgrow. Widespread H. pylori findings: In recent stool tests, >90% of her patients are now positive for H. pylori. H. pylori: Is a mast-cell activator Classically associated with stomach ulcers, but also with pancreatic cancer Meredith notes a personal family loss to pancreatic cancer in someone with prior H. pylori. Testing approaches: Functional medicine: GI-MAP (DNA-based) often picks up H. pylori even when: Breath tests, Endoscopic biopsies, or Traditional antibody tests come back negative. Distinguishes: Blood antibodies – tell you if you've ever had H. pylori, not necessarily current infection. Stool antigen/DNA – better for current infection. When to treat: She monitors elastase-1 (pancreatic enzyme output) on stool testing: Low elastase suggests H. pylori may be impairing stomach acid and downstream digestion. Treatment approach: Main tool: Mastic gum (a Mediterranean shrub extract) twice daily. Sometimes bismuth/Pepto‑style support depending on symptoms. Ed notes he often feels better whenever he uses mastic gum and now wants to test himself for H. pylori. Secretory IgA & post-COVID gut immunity: She's seeing dramatic reductions in secretory IgA (sIgA) on stool results—even in people in their 20s. sIgA = the primary immune antibody at the gut lining. Her working view: COVID appears to suppress gut immune function, making people more vulnerable to pathogens like H. pylori and histamine-producing bacteria. Core goal at Brio: heal leaky gut, rebuild sIgA, and restore gut-driven immunity. Clinic details: Brio Functional Medicine (Lee Highway “wellness corner” next to Nutrition World). Offers in‑person and telemedicine consultations. Contact: briomedicine.com and info@briomedicine.com. [0:35:42] – Dr. Curt Dearing on Blood Pressure & Conventional Medicine Historical BP Targets & Over-Lowering Risks Dr. Curt Dearing outlines four major issues with conventional blood pressure management. Evolving guidelines: 1977 Joint National Committee (JNC): Acceptable up to 160/95; treatment mainly when diastolic ≥105. JNC 5 and 7: 140/90 becomes standard; 130/80 suggested for high-risk (diabetes, CKD). 2017 ACC/AHA: 130/80 becomes diagnostic threshold. Some now push for “optimal” ~110/70. Curt's view: For older adults, the vascular system changes; some rise in BP is normal and necessary. Aggressively pushing older patients into 110s/60s can be harmful. J-curve phenomenon: As BP is lowered, risk decreases until a threshold, after which lower BP increases risk again. Key data he cites: 2018 Lancet (1+ million patients): No increased mortality at 150/100. American Journal of Hypertension: All-cause mortality increases at ~110/70 range. Practical implication: Very low BP (especially diastolic

Have you been struggling with gut issues for years, or suddenly have bloating, weird pain or digestive problems now that menopause is here? Are you one of those who cut out gluten hoping for relief, only to feel just as lousy (or worse)? We cover: Why your gut goes a little haywire in menopause, and why it has nothing to do with "just getting older" The gluten truth that made me rethink everything I put in my mouth (most of us get this completely backwards) How simply believing a food will hurt you can physically make it hurt you, and what that means for your power to change it A free international study you can join from your couch if you're dealing with IBS The one simple shift that beats probiotics and cutting out foods for a calmer gut   Associate Professor Jessica Biesiekierski is Head of Human Nutrition at the University of Melbourne and one of Australia's leading researchers in gut health, diet, and gut–brain interaction. Jess leads large international randomised controlled trials investigating how dietary and psychological interventions can improve gut conditions like Irritable Bowel Syndrome (IBS). Her work has been published in top journals including The Lancet, Gastroenterology, and The American Journal of Gastroenterology. She is internationally recognised for her research on non-coeliac gluten sensitivity, the low FODMAP diet, and how gut–brain mechanisms shape food-related symptoms. She currently leads the world-first head-to-head study comparing the low FODMAP diet with exposure-based cognitive behavioural therapy in people with IBS, recruiting across Australia and the USA.   Clinical trial — the Exclude or Expose Study in IBS — which is actively recruiting adults with IBS in both Australia and the USA. The trial compares two leading, evidence-based IBS treatments head-to-head for the first time: the low FODMAP diet (an exclusion-based dietary approach) versus exposure-based cognitive behavioural therapy (which works by helping the brain respond differently to gut symptoms and feared foods). Both are delivered entirely online over 12 weeks, free of charge, with one-on-one support from a dietitian or psychologist throughout. Many women experiencing gut symptoms around menopause may qualify. Trial website: www.gutresearchstudy.com NERVA app (gut-directed hypnotherapy): https://www.nervahealth.com/eu   Contact Jess Biesiekierskie: Email: gut-research@unimelb.edu.au University of Melbourne staff profile: https://findanexpert.unimelb.edu.au/profile/827643-jessica-biesiekierski Linkedin: https://www.linkedin.com/in/jessica-biesiekierski-78b61730/ Instagram: @human_nutrition_research Facebook: Human Nutrition Research Twitter: @jrbiesiekierski Give thanks to our sponsors: Try Vitali skincare. 20% off with code ZORA here - https://vitaliskincare.com Get Primeadine spermidine by Oxford Healthspan. 15% discount with code ZORA ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ - https://www.oxfordhealthspan.com/ZORA Get Mitopure Urolithin A by Timeline. 20% discount with code ZORA at https://timeline.com/zora Try MitoQ for optimal mitochondrial health. Code ZORA for 20% off https://mitoq.com/zora   Join the Hack My Age community on: YouTube: https://youtube.com/@hackmyage Facebook Page: ⁠⁠⁠⁠⁠@⁠Hack My Age⁠     Facebook Group: ⁠⁠⁠⁠⁠⁠@⁠Biohacking Menopause⁠⁠⁠⁠⁠⁠ ⁠   Biohacking Menopause Private Women's Only Support Group: https://membership.hackmyage.com/sales-page  Instagram: ⁠⁠⁠⁠⁠@⁠HackMyAge⁠    Website: ⁠⁠⁠⁠⁠⁠HackMyAge.com⁠    For partnership inquiries: https://www.category3.ca/  Some episodes of Hack My Age are supported by partners whose products or services may be discussed during the show. The host may receive compensation or earn a minor commission if you purchase through affiliate links at no extra cost to you. All opinions shared are those of the host and guests, based on personal experience and research, and do not necessarily represent the views of any sponsor. Sponsorships do not imply medical endorsement or approval by any healthcare provider featured on this podcast.

Twenty-five years ago, sequencing the human genome seemed poised to usher in an era of personalized medicine. Dr. Euan Ashley helped turn that promise into an actual clinical experiment, leading one of the first efforts to interpret an entire human genome in the context of a real patient's health. The challenge quickly became apparent: medicine could suddenly generate billions of data points about one person, but making sense of them was painfully slow.That history feels newly relevant. Ashley recently gave an AI system his own 15-year-old genome data and watched it reproduce most of an analysis that had originally required months of work by a team, in about 30 minutes. Meanwhile, genomics is being joined by wearables, multi-omics, and other technologies capable of tracking far more of our biology over time.In this episode of NextLevel, we use the genome revolution as a case study for what happens when our ability to measure the body advances faster than our ability to interpret and use the information. The next leap in personalized medicine may depend less on collecting another mountain of data than on building the tools, reference datasets, and healthcare systems capable of turning that information into decisions.Free course: Improve your metabolic healthGet our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://levels.link/wnl⁠

Rasmus Rosenberg Larsen is an Assistant Professor of Forensic Epistemology and Philosophy of Science at the University of Toronto and an Affiliated Scientist at the National Center for Ontological Research. His work lies at the intersection of psychology, epistemology and law, with research published in top-tier journals such as The Lancet. Rasmus is the author of the book, Psychopathy Unmasked: The Rise and Fall of a Dangerous Diagnosis, which offers a critical review of contemporary research and the judicial use of the controversial diagnosis commonly known as Psychopathic Personality Disorder or “psychopathy”.References for all texts cited in this podcast are on our Linktree.Presenters: Dr. Sally Tilt and Dr. Kerensa HockenProducers: Andrew Wilkie and Katie StokesYou can follow this podcast on LinkedIn by clicking here.The Forensic Psychology Podcast is a co-production between HM Prison and Probation Service and the Prison Radio Association charity. Hosted on Acast. See acast.com/privacy for more information.

Um estudo global da revista “The Lancet” revela que os transtornos mentais quase duplicaram, afetando 1,2 mil milhões de pessoas. Em análise, o aumento nos jovens e a fasquia da saúde mentalSee omnystudio.com/listener for privacy information.

durée : 00:15:08 - Les Matins de France Culture - Le réchauffement climatique va, lors des prochaines décennies, exposer les personnes âgées à une hausse des températures encore plus dangereuse que prévu, avance mardi une étude publiée dans le Lancet Planetary Health. - équipe : La Rédaction de France Culture, Margot Delpierre Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 00:15:08 - Journal de 8 h - Le réchauffement climatique va, lors des prochaines décennies, exposer les personnes âgées à une hausse des températures encore plus dangereuse que prévu, avance mardi une étude publiée dans le Lancet Planetary Health. - équipe : La Rédaction de France Culture, Margot Delpierre Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 00:15:08 - Les journaux de France Culture - Le réchauffement climatique va, lors des prochaines décennies, exposer les personnes âgées à une hausse des températures encore plus dangereuse que prévu, avance mardi une étude publiée dans le Lancet Planetary Health. - équipe : La Rédaction de France Culture, Margot Delpierre Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

PCOS Is Now PMOS. What the New Name Changes About How You Get Treated For decades, the diagnosis pointed at your ovaries. Cysts. Fertility. Birth control to regulate the cycle, and a shrug for everything else. This year, that changed. Polycystic ovary syndrome was formally renamed polyendocrine metabolic ovarian syndrome, or PMOS, in a global consensus published in The Lancet. The point was not cosmetic. It was an admission that this was never really a gynecological problem. Dr. Terri sits down with Dr. Cassie Smith, MD, dual board-certified endocrinologist, founder of Modern Endocrine, and author of Fix Your Gut, Fix Your Hormones, recorded on location at the EVEXIAS provider training. Dr. Smith has been making this argument for years, long before the literature caught up: the insulin, the inflammation, and the gut come first. The hormones are downstream. And if you only treat the hormones, you never actually fix anything. The conversation runs from the patient who was thin, had no cysts, had one symptom, and whose insulin nobody ever checked, all the way to what is happening right now with GLP-1s, the telehealth prescribing free-for-all, and the muscle loss almost nobody is monitoring. If you have been told your cycles are irregular and handed a prescription, if you are thin but feel metabolically off, or if you are on a GLP-1 and wondering whether you are doing it right, this one is for you. What you'll discover: 00:00 PCOS is officially renamed PMOS, and why the shift moves the focus off the ovaries entirely 00:59 The six different presentations of PCOS, including lean patients with no cysts and normal testosterone 01:42 The thin patient with one symptom, an irregular cycle, and an insulin level nobody ever ordered 03:33 The metabolic dumpster fire: how gut dysfunction drives estrogen, progesterone, insulin, and cortisol out of balance 04:08 What actually happens when you come off birth control after years of symptom suppression 05:36 The lab panel Dr. Smith runs first, including Free T3, insulin, cortisol, and a gut study 06:28 The unsexy basics: sleep, real food, sunlight, walking, and getting off the phone at midnight 07:29 Delayed childbearing, coming off the pill at 33, and the fertility math nobody explains 09:29 Treating PMOS in perimenopause when fertility is no longer the goal 10:50 Low serum testosterone with high free testosterone, and what low SHBG is telling you 11:50 The estrobolome: the gut bacteria responsible for recycling your estrogen 13:39 Why endocrinology and gynecology both missed this for so long 15:32 Fat cells as a full endocrine organ, and the signals they send when they are overfull 17:29 Ten thousand smoke signals: how inflammatory cytokines confuse your immune system 19:51 Skinny fat explained, and how you can be thin with the metabolic profile of someone who isn't 22:09 GLP-1s: what they do well, and how they are being prescribed badly 22:53 There is no magic bullet, and why your health is rent, not something you own 24:34 Telehealth vial-and-titration prescribing, the gray market, and patients with no follow-up 26:52 Doing it correctly: body composition scans, protein, resistance training, realistic timelines 29:44 GLP-1s slow gut motility. What Dr. Smith does to protect the gut long term 30:05 Fiber, hydration, and the two steps that changed one patient's life before she lost a pound The rename was the easy part. Now somebody has to start treating the whole system. The Dr. Terri Show is presented by EVEXIAS Health Solutions. For more, visit: https://www.evexias.com Connect with Dr. Terri:

This hour we take a look at some of the stories making headlines before talking with Clare Ath of the Human Coalition, who gives us an update on where the fight for abortion funding stands and what Massachusetts did that is stunning the country. Then Wesley Smith will discuss why The Lancet declares wildfires the next health crisis and what just happened to a Kentucky organ procurement organization. Get ready to think critically and biblically.Become a Parshall Partner: http://moodyradio.org/donateto/inthemarket/partnersSee omnystudio.com/listener for privacy information.

Dr. Aaron S. Zelikovich discusses the phase 3 NIMBLE trial of cemdisiran, an siRNA targeting complement component 5, for the treatment of generalized myasthenia gravis.  Show citation:  Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:10.1016/S0140-6736(26)00690-2 

Disclaimer: This episode and article are for educational purposes only and are not a substitute for individualized medical advice. Always consult your physician before making changes to your diet, exercise routine, or medications.TL;DR* The CDC's top 10 causes of death account for roughly 74% of all deaths in the US each year, and up to 80% of chronic disease is estimated to be driven by lifestyle factors — diet, movement, sleep, stress, and toxin exposure. * This episode goes cause by cause (heart disease, cancer, COVID/respiratory disease, accidents, stroke, Alzheimer's, diabetes, kidney disease, flu/pneumonia, and suicide) and lays out what the peer-reviewed research says about preventing, slowing, or reversing each one.* Ready to build your own plan? Book a free Metabolic Blueprint Session →The List, and the Number That Should Keep You Up at NightAccording to the CDC, ten conditions account for about 74% of all deaths in the United States every year:* Heart disease* Cancer* COVID-19 / chronic lower respiratory diseases* Accidents (unintentional injuries)* Stroke* Alzheimer's disease* Diabetes* Kidney disease* Influenza and pneumonia* SuicideHere's the part that doesn't get said enough: research estimates that up to 80% of chronic disease is driven by lifestyle factors — diet, movement, sleep, stress, and toxin exposure. Those aren't destinies. They're decisions, and decisions can change.A landmark paper in the Journal of the American Medical Association found that poor diet alone accounts for more deaths in the US than tobacco use. The fork may be more dangerous than the cigarette. And yet, most patients who end up on four to six medications were never once asked what they eat, how they sleep, or whether they move their bodies before those prescriptions were written. That's the difference between a sick care system and a healthcare system.Heart Disease and Stroke: The Most Reversible Disease We KnowHeart disease kills one American every 34 seconds and has held the #1 spot for over a century. But it's also one of the most reversible conditions in medicine.In 1990, Dr. Dean Ornish's landmark Lifestyle Heart Trial showed that intensive lifestyle changes — diet, exercise, stress management, and social support — could reverse coronary artery disease without drugs or surgery. Arterial plaques reduced. Blood flow improved. Chest pain decreased. A 2019 study in the Journal of the American College of Cardiology confirmed it: a plant-predominant diet, regular aerobic exercise, not smoking, and a healthy weight reduced cardiovascular risk by over 80%.What that looks like in practice:* A Mediterranean or whole-food, plant-based diet rich in omega-3s and antioxidants (this isn't the only diet that works — it's the broadest evidence-backed baseline)* Zone 2 cardio (low-intensity aerobic work, three to five times a week — a brisk walk counts)* Managing chronic inflammation, the real driver of arterial plaque formation* Reducing refined sugar and seed oils, which damage the endothelial lining of the arteries* Prioritizing sleep, since poor sleep spikes cortisol and directly harms the heartStroke follows the same playbook: control blood pressure through diet, exercise, and stress reduction. The DASH diet in particular has been shown in multiple studies to lower blood pressure as effectively as medication in many patients.Cancer: 30–50% Preventable, and Possibly More Metabolic Than GeneticTo be clear, this isn't a claim about curing cancer — it's about how much prevention research is available and underused. The World Health Organization estimates that 30–50% of cancers are preventable. The American Institute for Cancer Research has identified lifestyle factors that dramatically reduce risk across multiple cancer types:* Diet. A 2022 meta-analysis in The Lancet linked poor dietary patterns — low fiber, low fruit/vegetable intake, high processed meat — to one in five cancer deaths globally.* Obesity. Excess weight is now the second-leading risk factor for cancer after smoking, because fat tissue is metabolically active and produces hormones like estrogen and inflammatory cytokines that fuel cancer growth.* Exercise. A 2019 study of over 1.4 million people found higher physical activity was associated with lower risk across 13 cancer types, including breast, colon, and endometrial cancer.* Fasting and metabolic health. Emerging research on intermittent fasting and time-restricted eating shows it can lower insulin-like growth factor, a key promoter of cancer cell proliferation.* Toxin reduction. Chronic low-grade exposure to pesticides, plastics (BPA, phthalates), and environmental pollutants has been linked to increased cancer risk. Choosing organic where possible, filtering water and air, and reducing plastic in cookware and storage all matter.There's also a deeper shift happening in how researchers understand cancer itself. It's long been treated primarily as a genetic disease, but the evidence is increasingly pointing toward cancer as a metabolic disease. Dr. Thomas Seyfried at Boston College has done groundbreaking work showing that cancer cells overwhelmingly rely on glucose and glutamine fermentation for energy — which is why a ketogenic or low-glycemic approach may help starve cancer cells while protecting healthy ones. The research is still evolving, but it's compelling.Think of your body like a garden. You can water it, enrich the soil, and pull the weeds — or you can dump sugar and chemicals on it and wonder why nothing grows right. Disease doesn't happen to you. It grows in an environment you create, consciously or not. The good news: you can change that environment starting today.Alzheimer's: “Type 3 Diabetes”Alzheimer's is rising, and it's terrifying to watch someone go through it. But emerging science shows it has a strong lifestyle and metabolic component — researchers now sometimes call it “type 3 diabetes” because of the profound link between insulin resistance and neurodegeneration.Dr. Dale Bredesen's ReCODE Protocol, published in the Journal of Aging, showed that a multimodal lifestyle intervention — diet, exercise, sleep optimization, hormone balancing, and stress reduction — reversed early cognitive decline in the majority of patients treated. In his 2014 case series, 9 of 10 patients with early Alzheimer's or mild cognitive impairment showed measurable improvement, with several returning to work.Key strategies from the research:* Sleep is non-negotiable. The brain's glymphatic (waste clearance) system activates primarily during sleep, flushing out amyloid beta plaque. Poor sleep means plaque buildup.* Exercise. A 2020 study showed aerobic exercise increases BDNF (brain-derived neurotrophic factor) — essentially fertilizer for neurons — and reduces dementia risk by up to 35%.* Mediterranean-MIND diet. Shown to slow cognitive aging by an estimated 7.5 years in adherent individuals.* Blood sugar management. Insulin resistance in the brain disrupts its ability to use glucose for energy, effectively starving neurons.* Social connection. Harvard's 80-year longitudinal study found relationship quality was the single strongest predictor of cognitive health and longevity in old age.Type 2 Diabetes and Kidney Disease: One Disease Driving AnotherOver 37 million Americans have type 2 diabetes, and another 96 million are pre-diabetic. Here's the part that surprises people: type 2 diabetes is reversible in the majority of cases, and this isn't controversial — the science is overwhelming.The 2019 DiRECT trial, published in The Lancet, found that nearly half of type 2 diabetics achieved full remission through an intensive dietary intervention alone, with no medication. Other studies using low-carbohydrate and very-low-calorie diets have replicated these results consistently.Diabetic nephropathy — kidney damage from chronically high blood sugar — is the leading cause of kidney failure in the US. Control the upstream issue (blood sugar and metabolic dysfunction) and you protect the downstream organ.The diabetes reversal framework from the research:* Dramatically reduce refined carbohydrates and added sugars to blunt insulin spikes and reduce fat storage in the liver and pancreas* Practice time-restricted eating or intermittent fasting to improve insulin sensitivity* Add resistance training — muscle is your biggest glucose sink, so more muscle means better blood sugar control* Reduce visceral fat (the fat around and inside your organs), a key driver of insulin resistance and inflammationIf this list feels like a lot, that's fair. But it's not about blame — it's about empowerment. You have more control over your health outcomes than the medical system has typically told you.Respiratory Disease, Flu, and PneumoniaChronic lower respiratory diseases like COPD and emphysema are largely driven by smoking and air quality. Quitting smoking remains the single most impactful intervention here, full stop.For flu and pneumonia risk, immune resilience matters: vitamin D optimization, zinc and elderberry, and gut microbiome health (roughly 70% of your immune system lives in your gut). Even mild sleep deprivation has been shown to quadruple susceptibility to viral infection.Suicide and Mental HealthThis is the cause of death nobody wants to talk about, but it's in the top 10 — and it's the leading cause of death for men under 50, and the second-leading cause of death for people ages 10–34.While this is complex and deeply personal, research points to several lifestyle levers:* Exercise functions as an effective antidepressant, largely through endorphin release* The gut-brain axis matters more than most people realize — over 75% of the body's serotonin is produced in the gut, so gut health directly shapes brain chemistry* Social connection and purpose. Viktor Frankl's Man's Search for Meaning, written while he was in a Nazi concentration camp, captured this: meaning and connection to purpose are essential for survival, and perspective shapes both physiology and outcome* Reducing alcohol, a central nervous system depressant that worsens anxiety and depression despite short-term reliefIf you or someone you love is struggling, crisis hotlines are available 24/7. There's often a reason it's happening, and there's often a way through it.The Common ThreadAcross every single one of these conditions — heart disease, stroke, cancer, Alzheimer's, diabetes, kidney disease, respiratory disease, immune function, mental health — the same five levers keep showing up: diet, exercise, sleep, toxin reduction, and blood sugar balance.Your daily habits are either building disease or building resilience. Every meal, every walk, every night of good sleep compounds — just like interest in a bank account.This Week's Action Plan* Do a food audit. For the next three days, write down everything you eat. No judgment, just awareness — you can't change what you can't see.* Walk 30 minutes a day. It lowers blood pressure, improves insulin sensitivity, boosts BDNF, and reduces cortisol. Simple, not easy — do it anyway.* Optimize your sleep. Consistent bedtime, dark room, cool temperature, no screens.* Get your labs done. Know your fasting glucose, A1C, CRP, vitamin D, triglycerides, and LDL — these are your early warning systems.* Address one stress source this week. A conversation you need to have, a boundary you need to set, or ten minutes of breathwork. Chronic stress is silently killing you — take action on it.Ready for a Real Plan?If you're ready to take your health seriously and want a clear roadmap instead of guesswork, book a Metabolic Blueprint Session. In 30–45 minutes, we'll walk through your top three priority areas and how programs like the Metabolic Momentum Accelerator, the Cellular Reboot Accelerator, and the Total Health Restore Protocols can help.Schedule your complimentary consult →Know someone this could help? Share this episode with them — it might change or even save their life.If this episode was valuable, leaving a review on Spotify or Apple Podcasts helps this show reach more people.ReferencesStudies and sources cited in this episode:* CDC — Leading Causes of Death data* Journal of the American Medical Association (JAMA) — poor diet and US mortality* Ornish, D. et al. (1990) — The Lifestyle Heart Trial* Journal of the American College of Cardiology (2019) — plant-predominant diet, exercise, and cardiovascular risk reduction* DASH diet research on blood pressure control* World Health Organization (WHO) — cancer preventability estimates* American Institute for Cancer Research — lifestyle and cancer risk* The Lancet (2022 meta-analysis) — dietary patterns and cancer deaths* Physical activity and cancer risk study (2019, ~1.4 million participants)* Seyfried, T., Boston College — cancer as a metabolic disease* Bredesen, D., Journal of Aging — the ReCODE Protocol; 2014 case series* BDNF and exercise study (2020) — dementia risk reduction* Mediterranean-MIND diet and cognitive aging research* Harvard Study of Adult Development (80-year longitudinal study) — relationships and longevity* DiRECT Trial, The Lancet (2019) — type 2 diabetes remission through dietary intervention* Frankl, V. — Man's Search for MeaningThis article summarizes claims and studies as presented in the podcast episode. Listeners are encouraged to review primary sources directly and consult their own physician before making health decisions. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit tripleplaydoc.substack.com/subscribe

Welcome to the latest episode (August 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates: Hirsh Elhence, Jennifer L. Dodge, Stephen Fuest, et al. National Prevalence of Clinical Obesity by BMI Class: A National Cross-Sectional Study. Ann Intern Med. [Epub 2 June 2026]. doi:10.7326/ANNALS-25-05287 Eva Johnsen, et al. Achieving at Least 15% Weight Loss Within 2 Years of Type 2 Diabetes Diagnosis Is Associated With Lower Risks of Macrovascular and Microvascular Complications: A U.K. Cohort Study. Diabetes Care 20 July 2026; 49 (8): 1480–1489. doi.org/10.2337/dc26-0937 Carel W. le Roux, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England Journal of Medicine June 2026 DOI: 10.1056/NEJMoa2600751 Yu Wang, Shichao Tang, Xilin Zhou, Ping Zhang. National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs Among U.S. Adults With Diabetes, 2000–2022. Diabetes Care 20 July 2026; 49 (8): 1414–1419. https://doi.org/10.2337/dc25-2040 Jelle M. Beernink, et al. Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial. Diabetes Care 20 July 2026; 49 (8): 1434–1441. https://doi.org/10.2337/dc26-0882 Welch M, Forst T, Jia W et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. The Lancet, 2026; 408, 125-140 DOI: 10.1016/S0140-6736(26)00800-7 Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health DOC Updates is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's three science and medical journals—Diabetes, Diabetes Care, and Diabetes, Obesity, and CardioMetabolic CARE. Intended for practicing physicians and health care professionals, DOC Updates discusses how the latest research is relevant in clinical practice. For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.

Today, we are taking a deep dive into an intervention that almost every labor and delivery unit in North America has adopted over the last decade: Quantitative Blood Loss, or QBL. ACOG first recommended quantitative blood loss assessment in Committee Opinion Number 794, published in December 2019. This opinion recommended that every birthing facility implement a standardized, quantitative method for measuring cumulative blood loss at all deliveries, replacing visual estimation as the default approach. This built on earlier ACOG efforts, including the 2015 reVITALize initiative, which standardized obstetric data definitions and defined postpartum hemorrhage using cumulative measured blood loss thresholds (≥1,000 mL regardless of delivery route, or blood loss accompanied by signs/symptoms of hypovolemia). We've all weighed sponges, measured calibrated drapes, and run the math. But here's the million-dollar question: Does measuring blood loss accurately, on its own, actually improve outcomes for patients? The answer is YES….and NO at the same time. Listen in for details as we discuss new data (July 2026 in AJOG) on this topic. 1. White A, Burns RN, Pruszynski JE, Ravindra D, Fin KX, Montgomery T, Jestes E, Ambia AM, Anyaehie B, Duryea EL. Establishing Normal Blood Loss Thresholds at the Time of Delivery Based on Quantitative Blood Loss. Am J Obstet Gynecol. 2026 Jul. DOI: 10.1016/j.ajog.2026.07.028. S0002-9378(26)00395-9. YMOB 16849.2. Quantitative Blood Loss in Obstetric Hemorrhage: ACOG COMMITTEE OPINION, Number 794.Obstetrics and Gynecology. 2019. Committee on Obstetric Practice3. Coomarasamy A, Devall AJ, Bell S, et al. Diagnosis and Treatment of Postpartum Haemorrhage: A Race Against Time. Lancet. 2026.

In the second edition of 'Quarterly catch-up', CMI Communications editors Emily McDonald and Erin McCreary round-up the biggest news in infectious diseases and review clinical microbiology and infectious diseases studies published in the second quarter of 2026 [1-4]. From Pneumocystis jirovecii pneumonia in solid-organ-transplant recipients to a double-blind randomised controlled trial reporting a new antibiotic for complicated urinary tract infections, Erin and Emily highlight four articles they found particularly noteworthy, and comment on whether the results can and should change clinical practice.  ReferencesAlanio A, et al. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a prospective observational cohort study, J Infect 2026. DOI: 10.1016/j.jinf.2026.106794Ramendra R, et al. Procalcitonin to guide 7 versus 14 days of antibiotics in bloodstream infections: a secondary analysis of the BALANCE trial, JAMA Netw Open 2026. DOI: 10.1001/jamanetworkopen.2026.20973Pai MP, et al. Challenging weight-tiered antibiotic prophylaxis in obese patients undergoing colorectal surgery using CT-derived body composition, CID 2026. DOI: 10.1093/cid/ciag383 Takahashi S, et al. Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial. Lancet 2026. DOI: 10.1016/S0140-6736(26)00596-9 Further readingThe SNAP Trial Group. Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia. NEJM 2026. DOI: 10.1056/NEJMoa2506905The SNAP Trial Group. Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial. Lancet 2026. DOI: 10.1016/S0140-6736(26)00761-0McCreary EK, et al. Communicable episode 26: SNAP out of it – rethinking anti-staphylococcal penicillins for S. aureus bacteremia, the SNAP trial PSSA/MSSA results. Communicable Podcast 2025. https://share.transistor.fm/s/2a3c3bb4  Ilges D, et al. Anticalcitonin: limited utility of a context-dependent biomarker demonstrated in another real-world data set, CID 2026. DOI: https://doi.org/10.1093/cid/ciag396 Spellberg B. Procalcitonin–An enigmatic anxiolytic biomarker, JAMA Netw Open 2026. DOI: 10.1001/jamanetworkopen.2026.20978 

Reference:  Perry DC, et al. Surgical fixation versus non-surgical care for children with a displaced medial epicondyle fracture of the elbow (the SCIENCE study): a multicentre, randomised controlled, superiority trial and economic evaluation. The Lancet 2026 Date: July 14, 2026 Guest Skeptics: Dr. Megan Terle is an orthopedic surgeon and Assistant Professor for Pediatrics and […] The post SGEM#517 : I Will Try to Fix You. Surgery or Not for Pediatric Displaced Medial Epicondyle Elbow Fractures first appeared on The Skeptics Guide to Emergency Medicine.

Quais foram os principais destaques científicos, alertas globais e resoluções regulatórias que marcaram a medicina nos últimos dias? Nesta edição de resumo semanal do Afya News, analisamos o maior registro de casos de sarampo em três décadas nos EUA e a resolução do Cremesp que limita o tempo de cirurgias plásticas estéticas a seis horas em São Paulo. Discutimos também as novas diretrizes da OMS e o estudo latino-americano no The Lancet para prevenção do declínio cognitivo, os achados da Sociedade Brasileira de Cardiologia sobre os benefícios cardiovasculares da amamentação para as mães, a ampliação do teleatendimento do SUS para dependência em apostas digitais e a gravidade do surto de Ebola no Congo. O Afya News apresenta notícias da medicina com informação confiável e atualizada no seu tempo. Criado pela Afya, o maior hub de educação e soluções para a prática médica do Brasil, nosso propósito é transformar a saúde junto com quem tem a medicina como vocação.Fontes do episódio aqui:⁠https://portal.afya.com.br/podcasts/afya-news/08-08-2026

Our kidneys do an incredible job filtering our blood every hour of every day. Most of us have two kidneys, and each one has about a million microscopic filters called glomeruli. Unlike the filters in our HVAC system, though, these filters cannot be replaced. But they do their work so well and unobtrusively that most of us don't even think about our kidney function. Although 37 million Americans have kidney trouble, the majority are unaware of their situation. Two tests could reveal how well the kidneys are working. What are they, and how often should you ask about them? At The People's Pharmacy, we strive to bring you up‑to‑date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, August 8, 2026, through your computer or smart phone (wunc.org). Here is a link so you can find which stations carry our broadcast. If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on August 10, 2026. What Are the Two Tests That Reveal Kidney Trouble? Chronic conditions like high blood pressure and diabetes put a strain on the kidneys. They are very common problems that signal the need for kidney function monitoring. Our guest expert, Dr. Samir Parikh, suggests that all of us should know our numbers. One is derived from the level of creatinine in the blood. This is normally part of a basic metabolic panel. Usually, the panel results will include a number for the estimated glomerular filtration rate (EGFR) calculated from the value for blood creatinine. The other crucial test is a urine test for protein. Keeping Kidneys Healthy by Staying Properly Hydrated One of the simplest tactics to keep kidneys healthy is to provide them with enough liquid. We get some fluid from the food we eat, which may be one reason eating fruits and vegetables seems to be good for us. They are full of water! We also need to drink fluid, and plain water is probably the best choice. It would be smart to use thirst as a guideline and make sure to drink when thirsty. We do avoid overdoing water consumption, though, as overloading the kidneys with more fluid than they can handle is dangerous as well. Medicines That Are Hard on the Kidneys We mentioned to Dr. Parikh the experience of an older friend, a devoted runner, who discovered that taking ibuprofen after a run reduced the likelihood of having to get up overnight to urinate. He reminded us and our listeners that nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, naproxen, celecoxib or meloxicam can be hard on the kidneys. That doesn't mean we shouldn't ever take such pain relievers, but perhaps we should try not to make it a habit. When we asked about other medicines that might be tough on the kidneys, he mentioned PPIs. Proton pump inhibitors such as omeprazole (Prilosec) or esomeprazole (Nexium) are often used to treat heartburn or other digestive symptoms. Regular use can put a strain on the kidneys, although the gastroenterologist recommending the medicine might not warn you of that side effect. We asked about environmental toxins and learned that heavy metals such as lead or arsenic can harm the kidneys along with other organs. We should make sure that the food we eat and the water we drink are not contaminated with such compounds. The Possible Benefits of Vitamin B Dr. Parikh has been studying how the kidneys respond to the B vitamin nicotinamide. The preliminary work he and his colleagues have done so far is promising. However, they have not conducted clinical trials to find out whether the vitamin could help people with early kidney disease. Because kidneys work so hard, they need a lot of energy to be produced by the mitochondria in their cells. Those mitochondria need NAD+ (nicotinamide adenine dinucleotide) to function at their best. Providing additional nicotinamide appears to help (Nature Reviews. Nephrology, Feb. 2020).  One to three grams a day appears to be safe and may be beneficial. Medications That Can Promote Kidney Health Some medicines initially developed for other conditions are proving to be helpful in treating kidney disease. In particular, these include diabetes drugs known as SGLT2 inhibitors like dapagliflozin (Farxiga) or empagliflozin (Jardiance). They help slow the decline of kidney function (New England Journal of Medicine, Nov. 4, 2022). GLP-1 agonists may also be familiar because they too are used to treat diabetes. Medications such as semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro, Zepbound) have made headlines as weight loss and diabetes meds, but they also can reduce the risk of kidney failure and other bad outcomes (Lancet. Diabetes & Endocrinology, Jan. 2025). The benefits of these types of drugs should give us hope that we can go from slowing the progression of kidney disease to stopping it in its tracks Taking Care of Your Kidneys We asked Dr. Parikh what we should be doing to care for our kidneys and keep them healthy. He urged us once again to know our numbers: most importantly, the numbers from the two tests we discussed, blood creatinine and urine protein. Other numbers that are important for kidney are our blood pressure and, for those with diabetes, HbA1c. In addition to paying attention to all those numbers, we need to embrace a lifestyle that will help keep them where they belong. That means following a heart-healthy diet, staying physically active and getting adequate sleep. This Week’s Guest Samir M. Parikh, M.D., FASN, is Professor of Internal Medicine and Pharmacology and Chair of Internal Medicine at the University of Texas Southwestern. He holds the Donald W. Seldin Distinguished Chair in Internal Medicine and the Ruth W. and Milton P. Levy, Sr., Chair in Molecular Nephrology. Dr. Samir Parikh, University of Texas Southwestern Listen to the Podcast The podcast of this program will be available Monday, August 10, 2026, after broadcast on Aug. 8. This week's podcast has additional information on a possible role for sodium bicarbonate (baking soda) for kidney function. We also discussed medical silos, and how that leads to gastroenterologists overlooking the kidney risks from PPIs. Also, what should prospective kidney donors consider? You can stream the show from this site and download the podcast for free. Download the mp3, or listen to the podcast on Apple Podcasts or Spotify.

No Way But Forward: Remembering Families in the Gaza Strip   Join Michelle Villegas, host of Friends With The World, for a powerful and heartfelt conversation with psychologist and researcher Brian Barber PhD, author of No Way But Forward. For more than 25 years, Brian has studied and lived alongside Palestinian families, listening to their stories and witnessing their resilience, generosity, forgiveness, and deep commitment to one another. In this episode, Dr. Barber shares insights from his decades of research in the Gaza Strip, offering a deeper understanding of the lives, hopes, struggles, and humanity of families who often feel forgotten by the world. Together, Michelle and Brian explore the beauty of the human spirit, the importance of being seen and heard, and remembered. Bio: BRIAN K. BARBER, PhD, is a non-resident senior scholar at the Middle East Policy Council, a senior fellow at the Institute for Palestine Studies, and professor emeritus at the University of Tennessee. He currently lives in Washington, DC. Barber's work has addressed how context—from parenting to political systems—impacts individual and social development.Barber is the editor of Adolescents and War: How Youth Deal with Political Conflict (Oxford University Press, 2008), among other books. For the past thirty years, he has researched more than ten thousand Palestinian families in the West Bank, East Jerusalem, and the Gaza Strip. His published articles have appeared in The Lancet, Social Science & Medicine, Global Public Health, PLOS ONE, Child Development, the Journal of Adolescent Research, and other journals. Barber's commentaries have appeared in Haaretz, CNN.com, Informed Comment, Counterpunch, and Middle East Policy. His most recent book is No Way but Forward: Life Stories of Three Families in the Gaza Strip. Learn more about Michelle here  https://dreamvisions7radio.com/friends-with-the-world/ Website: friendswiththeworld.com

In the first episode of this special three-part series, Neil Skolnik speaks with Dr. Minesh Rajpal. Together, they provide an overview, discussing the assessment and management of high blood pressure. This special episode is sponsored with support from AstraZeneca. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Minesh Rajpal, MD, Attending Nephrologist and Hypertension Specialist at the Southwest Kidney Institute References: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee. Hypertension 2025; 82(10) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957

For decades, migraine was explained to patients as a blood vessel problem: swelling, throbbing, treat it by shrinking things back down. That explanation is mostly a myth, and it may be part of why so many older treatments never worked.Dr. Fred Cohen is medical director of Headache Intervention and an assistant professor of medicine and neurology at the Icahn School of Medicine at Mount Sinai. He's one of the few headache specialists in the country trained in both internal medicine and headache medicine, has over 40 publications in journals including The Lancet and Cephalalgia, and has lived with migraine himself since his teens.In this conversation, you'll explore:Why migraine is a neuroinflammatory condition, not a vascular one, and why some medical schools still teach the outdated versionThe "broken thermostat" phenomenon of chronic sensitization, and how untreated migraine can convince your brain that constant pain is normalWhy only about 30% of people with migraine ever experience aura, and the surprising range of ways it can actually show upThe current treatment landscape, from triptans to CGRP therapies, Botox, neuromodulation devices, and what's coming nextWhy Dr. Cohen calls this the golden age of headache medicine, and what that means if you gave up on treatment years agoIf migraine has ever made you feel like your body was working against you, or like you'd already tried everything, this conversation will change how you see both.You can find Fred at: Website | Instagram | Episode TranscriptNext week, we're sitting down with Marisa Renee Lee to talk about why the tidy stories we tell ourselves about grief and resilience tend to fall apart, and what it actually looks like to build a life around pain instead of waiting to get past it. Be sure to follow Good Life Project wherever you get your podcasts so you don't miss any upcoming episodes!Check out our sponsors and resources: Visit Our Sponsor Page Hosted on Acast. See acast.com/privacy for more information.

287 million people live with viral hepatitis worldwide. But vaccination and treatment offer new hope that elimination is possible. Lancet editor Niall Boyce discusses progress and challenges with Dr John Ward, Director of the Coalition for Global Hepatitis Elimination at the Task Force for Global Health. Visit https://www.taskforce.org/viral-hepatitis/ and https://www.worldhepatitisday.org/ to find out more. The Lancet Voice is part of the Lancet Group podcast offering.  Editorial team: Niall Boyce, Miriam Sabin, Jessamy Bagenal, Richard Horton, and Gavin Cleaver Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr. Jimenez cites a 2024 Lancet study reporting a 79% rise in cancer among young adults globally between 1990 and 2019, with a 28% increase in deaths, across 17 cancer types. He attributes this to environmental toxins, obesity, diet, and early-life exposures, and names three top toxicities he targets in treatment: aluminum, glyphosate, and EMF radiation. He walks through daily detox practices (coffee enemas, shilajit, hydrogen water) and practical EMF-reduction steps (Wi-Fi off at night, phone away from the bed, grounding sheets). He explains when Hope4Cancer still uses chemo, radiation, or surgery — low-dose IPT chemo for tumor debulking, targeted "spot radiation" for pain control, and stents for obstructions — despite the clinic's non-toxic-first philosophy. He then details the clinic's "seven key principles," spending the most time on emotional/spiritual health (his upcoming book, Emotions and Cancer, out March 2025) and introduces Davida, a new five-part bioimmunotherapy meant to upregulate the immune system without targeting specific cancer-cell receptors (unlike checkpoint inhibitors such as Opdivo/Keytruda). Host Jim, a stage IV melanoma survivor, shares his own remission story, and Dr. Jimenez recommends he ask his oncologist about the Signatera circulating-tumor-cell test for ongoing monitoring.HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please take advantage of our FREE resources below to help you along your health and healing journey:Support Group DirectoryHolistic Curriculum - Participant GuideSupport Our Mission - DonateAdditional Health ResourcesListen to Previous EpisodesWebsite: healingstrong.org

What if some of the most powerful ways to improve your health didn't require expensive gadgets, complicated routines, or the latest supplement trend? In this rapid-fire solo episode, Darin shares 15 unusual, science-backed habits that can dramatically improve longevity, mobility, brain function, nervous system regulation, digestion, and overall vitality. From dead hangs and deep squats to humming, sunlight, boredom, and chewing your food more thoroughly, each practice is grounded in published research, not internet biohacking hype. These are simple, practical habits you can start today that may have an outsized impact on your health over time. If you're looking for evidence-based ways to optimize your body without spending a fortune, this episode is packed with actionable takeaways. What You'll Learn Why grip strength may be one of the strongest predictors of longevity How deep squats improve mobility and joint health The surprising connection between balance and lifespan Why humming boosts nitric oxide production The science behind mouth taping and nasal breathing How cold water can instantly calm your nervous system Why boredom fuels creativity and brain function The health benefits of intentional silence How awe can reduce inflammation Why soil microbes strengthen your immune system The importance of chewing for nutrient absorption Why sunlight is one of the most powerful daily health tools Chapters 00:00:00 – Welcome to SuperLife 00:00:32 – Sponsor: Tru Niagen 00:02:35 – 15 science-backed health habits you probably aren't doing 00:04:18 – #1 Grip strength and longevity 00:06:40 – #2 The deep squat rest 00:08:16 – #3 Single-leg balance 00:09:36 – #4 Why humming boosts nitric oxide 00:11:01 – #5 Mouth taping and nasal breathing 00:12:41 – #6 Cold water face immersion 00:14:05 – #7 Ice on the back of your neck 00:14:59 – Sponsor: Manna Vitality 00:16:55 – #8 Getting bored on purpose 00:18:34 – #9 Scheduling daily silence 00:20:01 – #10 Chasing awe instead of scrolling 00:21:20 – #11 Why getting your hands dirty boosts immunity 00:23:00 – #12 Chewing your food more thoroughly 00:24:20 – #13 Squatting while using the bathroom 00:25:41 – #14 Get sunlight before your phone 00:26:59 – #15 Sunlight on your skin 00:28:28 – The complete 15-step daily protocol 00:29:05 – Start with one habit today 00:29:26 – Final thoughts and closing message Thank You to Our Sponsors Tru Niagen: Boost NAD+ levels for cellular health and longevity. Get 20% off with code DARINOLIEN20 at truniagen.com. Manna Vitality: Go to mannavitality.com/ and use code DARIN for 20% off your order. Join the SuperLife Community Get Darin's deeper wellness breakdowns — beyond social media restrictions: Weekly voice notes Ingredient deep dives Wellness challenges Energy + consciousness tools Community accountability Extended episodes Join for $7.49/month → https://patreon.com/darinolien Connect with Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness Key Takeaway "Better health doesn't always come from doing more—it often comes from returning to the simple things humans have done for thousands of years. Move your body naturally. Breathe through your nose. Spend time in silence. Get into the sun. Touch the earth. Challenge your balance. Strengthen your grip. These aren't expensive biohacks—they're timeless biological signals that remind your body how to thrive. Small daily actions, repeated consistently, can create extraordinary long-term health." Bibliography/Sources Physical Function & Biomechanics Araujo, C. G., et al. (2022). Successful 10-second one-legged stance performance predicts survival in middle-aged and older individuals. British Journal of Sports Medicine https://www.frontiersin.org/journals/sports-and-active-living/articles/10.3389/fspor.2022.1066913/full Deep squat / ankle dorsiflexion as clinical mobility assessment. (n.d.). PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC7276781/ https://pmc.ncbi.nlm.nih.gov/articles/PMC12358486/ Leong, D. P., et al. (2015). Prognostic value of grip strength: Findings from the Prospective Urban Rural Epidemiology (PURE) study. The Lancet, 386(9990), 266–273. https://doi.org/10.1016/S0140-6736(14)62000-6 Sikirov, D. (2003). Comparison of straining during defecation in three positions: Results and implications for human health. Digestive Diseases and Sciences, 48(7), 1201–1205. https://doi.org/10.1023/A:1024180319005 Respiratory & Nervous System Effects of cold stimulation on cardiac-vagal activation in healthy participants: A randomized controlled trial. (n.d.). PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC6334714/ Systematic review of mouth taping for sleep-disordered breathing. (2024). PLOS One. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0323643 Trigeminocardiac / mammalian dive reflex response to cold facial immersion. (2023). PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC10295257/ Weitzberg, E., & Lundberg, J. O. N. (2002). Humming greatly increases nasal nitric oxide. American Journal of Respiratory and Critical Care Medicine, 166(2), 144–145. https://pubmed.ncbi.nlm.nih.gov/12119224/ Brain, Silence & Emotion Bartoli, E., et al. (2024). Default mode network electrical stimulation effects on creativity. Brain, 147(10), 3409+. Bernardi, L., Porta, C., & Sleight, P. (2006). Cardiovascular, cerebrovascular, and respiratory changes induced by different types of music in musicians and non-musicians: The importance of silence. Heart, 92, 445–452. https://pubmed.ncbi.nlm.nih.gov/16199412/ Mann, S., & Cadman, R. (2014). Does being bored make us more creative? Creativity Research Journal, 26(2), 165–173. https://doi.org/10.1080/10400419.2014.901073 Münzel, T., et al. (2024). Noise causes cardiovascular disease: It's time to act. Journal of Exposure Science & Environmental Epidemiology. https://pmc.ncbi.nlm.nih.gov/articles/PMC11876066/ Stellar, J. E., John-Henderson, N., Anderson, C. L., Gordon, A. M., McNeil, G. D., & Keltner, D. (2015). Positive affect and markers of inflammation: Discrete positive emotions predict lower levels of inflammatory cytokines. Emotion, 15(2), 129–133. Immune, Digestion & Environmental Light Cassady, B. A., Hollis, J. H., Fulford, A. D., Considine, R. V., & Mattes, R. D. (2009). Mastication of almonds: Effects of lipid bioaccessibility, appetite, and hormone response. The American Journal of Clinical Nutrition, 89(3), 794–800. https://pubmed.ncbi.nlm.nih.gov/19144727/ Liu, D., Fernandez, B. O., Hamilton, A., et al. (2014). Isolated UVA irradiation of human skin generates dermal nitric oxide and lowers blood pressure independent of vitamin D. Journal of Investigative Dermatology, 134(7), 1839–1846. https://pubmed.ncbi.nlm.nih.gov/24445737/ Morning light exposure and circadian phase-shifting / dim-light melatonin onset. (n.d.). PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC10594521/ Rook, G. A. W., et al. (2023). The old friends hypothesis: Evolution, immunoregulation and essential microbial inputs. Frontiers in Allergy. https://pmc.ncbi.nlm.nih.gov/articles/PMC10524266/ Strachan, D. P. (1989). Hay fever, hygiene, and household size. BMJ, 299(6710), 1259–1260. https://doi.org/10.1136/bmj.299.6710.1259

CardioNerds (Drs. Apoorva Gangavelli, Jenna Skowronski, and Hannah Every) discuss the continuum of prevention and heart failure with Drs. Anu Lala and Martha Gulati. Grounded in a clinical case of a 55-year-old woman with uncontrolled hypertension, type 2 diabetes, and obesity who is on the trajectory toward heart failure, this episode unpacks a paradigm-shifting framework from a joint HFSA/ASPC Scientific Statement. The discussion explores how prevention should not be siloed from heart failure management but rather integrated across a patient’s lifespan—from primary prevention in at-risk individuals, to secondary prevention in those with established heart failure, to tertiary prevention in patients with advanced therapies such as LVADs and heart transplantation. The experts highlight the importance of aggressive risk factor management, biomarker-guided screening, the AHA’s Life’s Essential 8, and the need for multidisciplinary collaboration and systems-level change to shift heart failure care from reactive to proactive. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Prevention PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Systemic inflammatory diseases are associated with an elevated CVD risk that has significant implications for early detection, risk Heart failure prevention is a continuum, not a checkpoint. Prevention applies at every stage—from at-risk (Stage A) through advanced/post-transplant care—and every clinical encounter is an opportunity to intervene. The AHA’s Life’s Essential 8 (diet, physical activity, nicotine exposure, sleep, BMI, blood lipids, blood glucose, blood pressure) forms the foundation at every stage. Hypertension carries the highest population-attributable risk for heart failure of any modifiable risk factor. In the Framingham Heart Study, 91% of patients with newly diagnosed HF had pre-existing hypertension. The SPRINT trial demonstrated a 38% reduction in HF incidence with intensive blood pressure targets (30 ng/L or NT-proBNP >125 ng/L) identify individuals at heightened risk for progression to symptomatic HF. The ACC/AHA/HFSA guidelines give a Class IIa recommendation for natriuretic peptide screening in at-risk patients. Urine albumin-to-creatinine ratio (UACR) is an underutilized screening tool that provides additional insight into CKM risk. The heart failure label does not close the prevention window—it accentuates it. Secondary prevention through GDMT optimization (quadruple therapy in HFrEF) and continued risk factor management remains critical. Tertiary prevention extends to post-LVAD and post-transplant patients, where hypertension, diabetes, obesity, and CKD management remain essential to long-term outcomes. Show notes For a comprehensive review, please review the full HFSA/ASPC Joint Scientific Statement: Lala A, Beavers C, Blumer V, et al. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine. J Card Fail. 2026;32:75-105. doi:10.1016/j.cardfail.2025.06.013 1. What is the “continuum of prevention” framework, and how does it differ from traditional approaches to heart failure prevention? Historically, prevention and heart failure management have been treated as separate disciplines—primary prevention handled by preventive cardiologists and treatment managed by heart failure specialists. This joint HFSA/ASPC Scientific Statement reframes prevention as a dynamic, continuous process that spans a patient’s entire lifespan, regardless of HF stage or ejection fraction. The framework maps onto the ACC/AHA HF staging system: Primary prevention targets Stage A (“at risk”) and Stage B (“pre-HF”) patients to reduce the burden of incident HF. Secondary prevention targets Stage C (symptomatic) and Stage D (advanced) patients to reduce the impact of established HF through GDMT optimization and ongoing risk factor management. Tertiary prevention encompasses risk factor management in patients with LVADs or heart transplants—populations where hypertension, diabetes, and obesity still drive outcomes. The Central Figure of the statement illustrates that Life’s Essential 8 (blood pressure and lipid control, diabetes management, exercise, sleep, smoking cessation, weight management, and diet/nutrition counseling) forms the foundation at every stage, with pharmacologic and device-based therapies layered on top as disease progresses (Figure) 2. How do traditional risk factors drive heart failure, and what should clinicians prioritize? Hypertension carries the greatest population-attributable risk for HF. In the Framingham Heart Study (N=5,143), HTN was associated with a 2- to 3-fold increased risk of HF, with a population-attributable risk of 39% in men and 59% in women. The SPRINT trial showed a 38% reduction in HF incidence and 25% reduction in the primary composite outcome with intensive BP targets (30 ng/L or NT-proBNP >125 ng/L) are associated with heightened risk for progression to symptomatic HF. In the ARIC study, incorporating NT-proBNP reclassified 20% of older adults without HF into Stage B. Factors that affect interpretation include age, sex, obesity (lower values), and CKD (higher values). High-sensitivity cardiac troponin (hs-cTn): Concentrations above the 99th percentile are now included in the definition of Stage B HF. Troponin testing may complement natriuretic peptides, particularly when BNP/NT-proBNP values are ambiguous. Risk scores: The PCP-HF equation predicts 10-year HF risk using traditional risk factors plus QRS duration. The AHA PREVENT score incorporates HF risk calculation and includes markers of kidney function (albuminuria, eGFR), though it may underestimate risk in men and Black adults. The CKM syndrome staging framework (Stages 0–4) provides a holistic approach to assessing systemic cardiovascular-kidney-metabolic risk. 4. What are the key nontraditional risk factors and cross-cutting themes in heart failure prevention? Genetics: Pathogenic cardiomyopathy variants exist in ~1 in 200 individuals in the general population. The HFSA and ACMG recommend cascade testing to identify at-risk family members. Polygenic risk scores for dilated cardiomyopathy show a 3.8-fold risk for DCM in the top 10th percentile compared with the median. Sex-specific considerations: Women have 2.8 times the odds of developing HFpEF, while men have similarly increased odds of HFrEF. A complete obstetric/gynecologic history is essential—preeclampsia is associated with a 4-fold increased risk of HF. Peripartum cardiomyopathy requires intentional screening in high-risk populations. Cardiotoxic exposures: Clinicians should be aware of medications that cause direct myocardial toxicity (e.g., anthracyclines, trastuzumab, tyrosine kinase inhibitors). A team-based approach with pharmacists can help optimize medication selection and risk factor modification. Social determinants of health: Environmental exposures (air pollution, arsenic, lead, cadmium), food insecurity, financial instability, and limited healthcare access contribute to HF risk and progression. Equity-focused, risk-based prevention strategies are needed. Psychological health: Depression is common in HF and independently associated with worse outcomes. Screening with brief questionnaires (e.g., PHQ-2) is recommended. Meditation, spirituality, and holistic wellness approaches remain underutilized. 5. What systems-level and policy changes are needed to move the needle on heart failure prevention? Multidisciplinary HF prevention clinics that bring together preventive cardiologists, HF specialists, endocrinologists, nephrologists, dietitians, pharmacists, exercise physiologists, and genetic counselors are advocated by the statement. EHR-embedded risk stratification could proactively flag patients on a trajectory toward HF—analogous to sepsis alerts or fall risk flags—enabling earlier intervention, particularly for patients who may not reach a cardiologist. Cardiac rehabilitation remains underutilized, particularly in HFrEF (Class 2b recommendation) and HFpEF (not yet covered by Medicare). The HF-ACTION trial showed quality-of-life benefits, and the REHAB-HF trial showed particular benefit in older patients with HFpEF. Policy priorities include expanding insurance coverage for preventive screening and novel therapies (SGLT2i, GLP-1 RAs, nsMRAs), reducing clinical inertia through team-based care models with closer follow-up intervals, and ensuring equitable access to evidence-based therapies across diverse populations. Digital health and AI hold promise for personalized risk prediction, remote monitoring (e.g., wearable devices, implantable PA pressure monitors), and virtual cardiac rehabilitation to overcome access barriers. Figure  Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013) References Key references are bolded. Lala A, Beavers C, Blumer V, et al. The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology. J Card Fail. 2026;32(1):75-105. doi:10.1016/j.cardfail.2025.06.013 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063 Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life’s Essential 8: updating and enhancing the American Heart Association’s construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation. 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078 SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116. doi:10.1056/NEJMoa1511939 Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-1562. doi:10.1001/jama.1996.03530440037034 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997. doi:10.1001/jama.288.23.2981 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301 Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720 Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 Filippatos G, Anker SD, Agarwal R, et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022;145(6):437-447. doi:10.1161/CIRCULATIONAHA.121.057983 Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786. doi:10.1016/S0140-6736(24)01498-3  Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636-1664. doi:10.1161/CIR.0000000000001175 Khan SS, Matsushita K, Sang Y, et al. Development and validation of the American Heart Association’s PREVENT equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart failure in the general population. J Am Coll Cardiol. 2019;73(19):2388-2397. doi:10.1016/j.jacc.2019.02.057 Bozkurt B, Fonarow GC, Goldberg LR, et al. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021;77(11):1454-1469. doi:10.1016/j.jacc.2021.01.030 Packer M. Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 2018;137(15):1614-1631. doi:10.1161/CIRCULATIONAHA.117.032474 Lala A, Tayal U, Hamo CE, et al. Sex differences in heart failure. J Card Fail. 2022;28(3):477-498. doi:10.1016/j.cardfail.2021.10.006 Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352-380. doi:10.1002/ejhf.2115 Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline. J Card Fail. 2018;24(5):281-302. doi:10.1016/j.cardfail.2018.03.004 Levine GN, Cohen BE, Commodore-Mensah Y, et al. Psychological health, well-being, and the mind-heart-body connection: a scientific statement from the American Heart Association. Circulation. 2021;143(10):e763-e783. doi:10.1161/CIR.0000000000000947 Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022;399(10333):1391-1400. doi:10.1016/S0140-6736(22)00369-5

¿Has escuchado maravillas sobre medicamentos como Ozempic, Wegovy o Mounjaro, pero nadie te habla de las constantes náuseas y el malestar estomacal? La realidad clínica es que una gran parte de los pacientes abandonan estos tratamientos para la obesidad simplemente porque los efectos secundarios arruinan su calidad de vida. Pero la ciencia médica está a punto de dar un salto monumental. En este episodio, descubriremos a la AMILINA, una hormona producida por tu páncreas que está demostrando resultados asombrosos en ensayos clínicos: pérdida de peso significativa sin los severos vómitos ni malestares intestinales de los fármacos actuales. En este episodio aprenderás: → Cómo tu páncreas libera dos hormonas cada vez que comes. → Cómo la amilina bloquea el freno metabólico que hace que recuperes el peso perdido. → Cómo dos equipos de investigadores resolvieron el mismo problema químico de formas distintas. → Cómo la combinación CagriSema alcanza una reducción significativa del peso corporal. → Por qué la amilina resensibiliza tu cerebro a la leptina, algo que la semaglutida no logra.   Mi nombre es Dr. Mauricio González, médico internista y especialista en endocrinología en formación. Aquí comparto información basada en evidencia para que tomes decisiones de salud sin mitos ni marketing engañoso. Suscríbete a mi boletín informativo en: www.drmauriciogonzalez.com/   ⚠️ Este podcast tiene fines exclusivamente educativos e informativos y no constituye asesoramiento médico, diagnóstico ni tratamiento personalizado. Los medicamentos que se discuten en este episodio se encuentran en fase de investigación y no cuentan con aprobación de la FDA. Consulta siempre a tu médico o a un profesional de la salud calificado antes de cambiar tu régimen de tratamiento.   ¡Sigamos la conversación en redes sociales! Instagram

Trump wants $95 billion more for his Iran war while oil giants cash in — and DNI pick Jay Clayton confesses to victimizing Epstein's victims. In this episode: • Hegseth testifies war money runs dry by August 1 — demands $87 to $95 billion more on top of a nearly $1 trillion budget • Hegseth admits $37.7 billion already spent, then warns we're low on ammo on camera • US bombing hits civilian desalination systems — 10,000 Iranians without drinking water • Oil near $90 a barrel, gas near $4 — Chevron, Exxon, ConocoPhillips feast while Hormuz stays shut • Jay Clayton clears committee 9–8 for Director of National Intelligence after he spilled Epstein victims' names, addresses, and photos • Clayton won't say Biden won 2020 — and shrugs at Tulsi helping seize Fulton County ballots • Tillis and Cornyn freeze Todd Blanche's Attorney General path after Epstein survivor meeting left victims more traumatized • Cornyn holds Kari Lake and Mastriano ambassadorships hostage over PEPFAR AIDS funding — Lancet warns 14 million dead if cuts stand, one third children • Ed Martin's pardon office ignores nearly 6,000 pleas for clemency so he can free Trump donors and Clean Air Act polluters • Sunny Hostin's Harvard grad son handcuffed jogging in New Rochelle Key figures covered: Donald Trump, Pete Hegseth, Jay Clayton, Todd Blanche, Thom Tillis, Jon Cornyn, Kari Lake, Ed Martin, Kash Patel, Chelsi "Sunny" Hostin Subscribe for live shows Sunday, Tuesday, and Thursday at 6:05 PM Eastern. Recorded live on the David Feldman Show July 21, 2026 #IranWar #EpsteinFiles #ToddBlanche #PeteHegseth #Trump #JayClayton #PEPFAR #WarSupplemental #OilPrices #DavidFeldmanShow

In this informative episode Dr. Tom Frieden former CDC director for eight years for President Obama shares his journey in public health. Tom discusses his 'See, Believe, Create' formula for better health, and insights on how individuals can contribute to global health improvements. Kimberly and Tom disscus practical tips for longevity, the importance of trust in public health, and stories from his global experiences, including Ebola and COVID-19 responses. Tom speaks about his new book; The Formula for Better Health: How to Save Millions of Lives and Your Own. Chapters00:00 Introduction to Dr. Tom Frieden's Journey02:56 The Philosophy of Service and Health05:47 Understanding the Formula: See, Believe, Create09:04 Navigating Misinformation in Public Health11:55 Experiences in Global Health: Ebola and Beyond14:51 Reflections on COVID-19 and Lessons Learned17:10 The Importance of Belief in Public Health19:59 The Legacy of Smallpox Eradication21:17 Preventable Health Issues Today23:19 Key Factors for a Healthy Life26:36 The Power of Physical Activity27:54 Nutrition and Its Impact on Health29:21 Environmental Toxins and Health Risks30:57 Fertility Challenges in Modern Society33:21 Creating a Healthier Future37:37 The Call to Action for Global HealthEpisode Sponsor: ANIMA MUNDI OFFER: Anima Mundi is giving Feel Good Podcast listeners their largest discount of the year. It's a great opportunity to treat yourself or a friend to some soothing self-care by going to AnimaMundiHerbals.com and use the code: SOLLUNA20 for 20% off your purchase. USE LINK: AnimaMundiHerbals.com Code: SOLLUNA20 for 20% off your purchase.Dr. Tom Frieden Resources: Book: The Formula for Better Health: How to Save Millions of Lives—Including Your OwnWebsite: resolvetosavelives.orgSocial: X @drtomfriedenBio: Dr. Tom Frieden is a physician specializing in internal medicine, infectious diseases, public health, and epidemiology. He led New York City's control of multidrug-resistant tuberculosis and other health threats, directed the CDC during the Ebola epidemic, and helped start Mayor Michael Bloomberg's global health philanthropy, particularly the Bloomberg Initiative to Reduce Tobacco Use, which has helped countries implement measures that will prevent more than 35 million deaths. His work has appeared in medical journals including The New EnglandJournal of Medicine, JAMA, and The Lancet as well as media outlets including the New York Times, Washington Post, and The Wall Street Journal. Dr. Frieden is the founder and CEO of Resolve to Save Lives, a global health organization that accelerates action against the world's deadliest health threats. The organization has partnered with countries around the world to support implementation of programs that will prevent more than 9 million deaths.Dr. Frieden's forthcoming book, The Formula for Better Health: How to Save Millions of Lives—Including Your Own (MIT Press, September 2025), distills four decades of public health leadership into a clear, actionable framework to extend healthy lives. Drawing from real-world successes and failures, the book bridges the lethal gap between scientific knowledge and life-saving action.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

After earning her first-class degree in chemistry from Oxford, Dorothy embarked on an impressive career in the new field of X-ray crystallography. She would ultimately earn many, many accolades for her work. Research: "Dorothy Crowfoot Hodgkin." Encyclopedia of World Biography Online, Gale, 1998. Gale In Context: Opposing Viewpoints, Biophysical Society. “Profiles in Biophysics: Dorothy Hodgkin.” 2016. https://www.biophysics.org/profiles/dorothy-hodgkin Boon, Rachel. “Curator Rachel Boon celebrates the work of Dorothy Hodgkin.” Science Museum. 12/10/2014. https://blog.sciencemuseum.org.uk/celebrating-dorothy-hodgkin-britains-first-female-winner-of-a-nobel-science-prize/ Bragg, Sir William. “Concerning The Nature Of Things.” London. Bell & Sons. 1932. https://archive.org/details/in.ernet.dli.2015.222386/ Bud, Robert. "Discoverers and developers of penicillin (act. 1928–1950)." Oxford Dictionary of National Biography. May 21, 2009. Oxford University Press. Date of access 22 Jun. 2026, https://www.oxforddnb.com/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-97279 Dodson, Guy. “Dorothy Mary Crowfoot Hodgkin, O.M. 12 May 1910--29 July 1994.” Biographical Memoirs of Fellows of the Royal Society , Dec., 2002, Vol. 48 (Dec., 2002). Via JSTOR. https://www.jstor.org/stable/3650256 DOROTHY CROWFOOT HODGKIN. NobelPrize.org. Nobel Prize Outreach 2026. Wed. 24 Jun 2026. https://www.nobelprize.org/stories/women-who-changed-science/dorothy-hodgkin/ Ferry, Georgina. "Dorothy Hodgkin". Encyclopedia Britannica, 8 May. 2026, https://www.britannica.com/biography/Dorothy-Hodgkin. Accessed 24 June 2026. Ferry, Georgina. "Hodgkin, Dorothy Mary Crowfoot (1910–1994), chemist and crystallographer." Oxford Dictionary of National Biography. May 21, 2009. Oxford University Press. Date of access 22 Jun. 2026, https://www.oxforddnb.com/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-55028 Ferry, Georgina. “Dorothy Hodgkin: A Life.” Bloomsbury. 1998, 2014. Ferry, Georgina. “Dorothy Hodgkin: on proteins and patterns.” The Lancet, 384, 1496-1497. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61912-7/fulltext Ferry, Georgina. “The making of an exceptional scientist.” Nature. Vol. 464. April 29, 2010. Gamble, Jessa. “When Hodgkin met Thatcher.” Nature. Vol. 514. October 16, 2014. Hodgkin, Dorothy Crowfoot. “The X-ray analysis of complicated molecules.” Nobel Lecture, December 11, 1964. https://www.nobelprize.org/uploads/2018/06/hodgkin-lecture-1.pdf Hodgkin, Dorothy. “The Pugwash Movement.” India International Centre Quarterly. Vol. 13, No. 2. June 1986. Via JSTOR. https://www.jstor.org/stable/23001474 Howard, Judith A.K. “Dorothy Hodgkin and her contributions to biochemistry.” Nature Reviews. Vol. 4. November 2003. gale.com/apps/doc/K1631003072/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=8d7c4045. Accessed 23 June 2026. Pearce, JMS. “Dorothy Crowfoot Hodgkin OM, FRS (1910-1994).” Hektoen International. https://hekint.org/2020/11/04/dorothy-crowfoot-hodgkin-om-frs-1910-1994/ Perutz, Max. “Dorothy Crowfoot ” The Independent. Via The Crystallographic Community. https://www.iucr.org/people/crystallographers/dorothy-crowfoot-hodgkin-by-m.f.-perutz Pietzsch, Jochim. “Perspectives: Enhancing X-ray vision.” Nobel Prize. https://www.nobelprize.org/prizes/chemistry/1964/perspectives/ Ramaseshan, S. “Dorothy Hodgkin and the Indian Connection.” Notes and Records of the Royal Society of London , Jan., 1996. http://www.jstor.com/stable/531845 Root-Bernstein, Robert. “Dorothy Crowfoot Hodgkin: Structure as Art.” Leonardo , 2007, Vol. 40, No. 3 (2007). Via JSTOR. https://www.jstor.org/stable/20206415 Science History Institute Museum and Library. “Dorothy Crowfoot Hodgkin.” https://www.sciencehistory.org/education/scientific-biographies/dorothy-crowfoot-hodgkin/ The Royal Society. “Dorothy Hodgkin FRS.” https://royalsociety.org/about-us/who-we-are/diversity-inclusion/case-studies/scientists-with-disabilities/dorothy-hodgkin/ “Science for peace Building cultures of cooperation and non-violence through scientific collaboration.” 2025. Via JSTOR. https://www.jstor.org/stable/resrep73183.6 University of Oxford History of Science Museum. “Modelling the Structure of Penicillin.” https://www.mhs.ox.ac.uk/backfromthedead/exhibition/the-structure-of-penicillin/index.html Vijayan, M. “An outstanding scientist and great humanist: An obituary of Dorothy Crowfoot Hodgkin.” Current Science, 10 August 1994, Vol. 67, No. 3 (10 August 1994). Via JSTOR. https://www.jstor.org/stable/24095820 Wallace, Rob. “Dorothy Crowfoot Hodgkin: Captured by Crystals.” National World War II 3/16/2022. https://www.nationalww2museum.org/war/articles/dorothy-hodgkin-penicillin-insulin See omnystudio.com/listener for privacy information.

Dorothy Hodgkin's career in X-ray crystallography impacted a lot of science in the 20th century. Part one of her story covers her early life and formative experiences that led her to her field of research. Research: "Dorothy Crowfoot Hodgkin." Encyclopedia of World Biography Online, Gale, 1998. Gale In Context: Opposing Viewpoints, Biophysical Society. “Profiles in Biophysics: Dorothy Hodgkin.” 2016. https://www.biophysics.org/profiles/dorothy-hodgkin Boon, Rachel. “Curator Rachel Boon celebrates the work of Dorothy Hodgkin.” Science Museum. 12/10/2014. https://blog.sciencemuseum.org.uk/celebrating-dorothy-hodgkin-britains-first-female-winner-of-a-nobel-science-prize/ Bragg, Sir William. “Concerning The Nature Of Things.” London. Bell & Sons. 1932. https://archive.org/details/in.ernet.dli.2015.222386/ Bud, Robert. "Discoverers and developers of penicillin (act. 1928–1950)." Oxford Dictionary of National Biography. May 21, 2009. Oxford University Press. Date of access 22 Jun. 2026, https://www.oxforddnb.com/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-97279 Dodson, Guy. “Dorothy Mary Crowfoot Hodgkin, O.M. 12 May 1910--29 July 1994.” Biographical Memoirs of Fellows of the Royal Society , Dec., 2002, Vol. 48 (Dec., 2002). Via JSTOR. https://www.jstor.org/stable/3650256 DOROTHY CROWFOOT HODGKIN. NobelPrize.org. Nobel Prize Outreach 2026. Wed. 24 Jun 2026. https://www.nobelprize.org/stories/women-who-changed-science/dorothy-hodgkin/ Ferry, Georgina. "Dorothy Hodgkin". Encyclopedia Britannica, 8 May. 2026, https://www.britannica.com/biography/Dorothy-Hodgkin. Accessed 24 June 2026. Ferry, Georgina. "Hodgkin, Dorothy Mary Crowfoot (1910–1994), chemist and crystallographer." Oxford Dictionary of National Biography. May 21, 2009. Oxford University Press. Date of access 22 Jun. 2026, https://www.oxforddnb.com/view/10.1093/ref:odnb/9780198614128.001.0001/odnb-9780198614128-e-55028 Ferry, Georgina. “Dorothy Hodgkin: A Life.” Bloomsbury. 1998, 2014. Ferry, Georgina. “Dorothy Hodgkin: on proteins and patterns.” The Lancet, 384, 1496-1497. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)61912-7/fulltext Ferry, Georgina. “The making of an exceptional scientist.” Nature. Vol. 464. April 29, 2010. Gamble, Jessa. “When Hodgkin met Thatcher.” Nature. Vol. 514. October 16, 2014. Hodgkin, Dorothy Crowfoot. “The X-ray analysis of complicated molecules.” Nobel Lecture, December 11, 1964. https://www.nobelprize.org/uploads/2018/06/hodgkin-lecture-1.pdf Hodgkin, Dorothy. “The Pugwash Movement.” India International Centre Quarterly. Vol. 13, No. 2. June 1986. Via JSTOR. https://www.jstor.org/stable/23001474 Howard, Judith A.K. “Dorothy Hodgkin and her contributions to biochemistry.” Nature Reviews. Vol. 4. November 2003. gale.com/apps/doc/K1631003072/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=8d7c4045. Accessed 23 June 2026. Pearce, JMS. “Dorothy Crowfoot Hodgkin OM, FRS (1910-1994).” Hektoen International. https://hekint.org/2020/11/04/dorothy-crowfoot-hodgkin-om-frs-1910-1994/ Perutz, Max. “Dorothy Crowfoot ” The Independent. Via The Crystallographic Community. https://www.iucr.org/people/crystallographers/dorothy-crowfoot-hodgkin-by-m.f.-perutz Pietzsch, Jochim. “Perspectives: Enhancing X-ray vision.” Nobel Prize. https://www.nobelprize.org/prizes/chemistry/1964/perspectives/ Ramaseshan, S. “Dorothy Hodgkin and the Indian Connection.” Notes and Records of the Royal Society of London , Jan., 1996. http://www.jstor.com/stable/531845 Root-Bernstein, Robert. “Dorothy Crowfoot Hodgkin: Structure as Art.” Leonardo , 2007, Vol. 40, No. 3 (2007). Via JSTOR. https://www.jstor.org/stable/20206415 Science History Institute Museum and Library. “Dorothy Crowfoot Hodgkin.” https://www.sciencehistory.org/education/scientific-biographies/dorothy-crowfoot-hodgkin/ The Royal Society. “Dorothy Hodgkin FRS.” https://royalsociety.org/about-us/who-we-are/diversity-inclusion/case-studies/scientists-with-disabilities/dorothy-hodgkin/ “Science for peace Building cultures of cooperation and non-violence through scientific collaboration.” 2025. Via JSTOR. https://www.jstor.org/stable/resrep73183.6 University of Oxford History of Science Museum. “Modelling the Structure of Penicillin.” https://www.mhs.ox.ac.uk/backfromthedead/exhibition/the-structure-of-penicillin/index.html Vijayan, M. “An outstanding scientist and great humanist: An obituary of Dorothy Crowfoot Hodgkin.” Current Science, 10 August 1994, Vol. 67, No. 3 (10 August 1994). Via JSTOR. https://www.jstor.org/stable/24095820 Wallace, Rob. “Dorothy Crowfoot Hodgkin: Captured by Crystals.” National World War II 3/16/2022. https://www.nationalww2museum.org/war/articles/dorothy-hodgkin-penicillin-insulin See omnystudio.com/listener for privacy information.